| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Synthetic Biology | 38 | 2025 | 186 | 10.560 |
Why?
|
| Schistosoma mansoni | 19 | 2021 | 154 | 7.490 |
Why?
|
| Escherichia coli | 63 | 2024 | 4214 | 7.400 |
Why?
|
| Anti-Bacterial Agents | 60 | 2024 | 7478 | 7.370 |
Why?
|
| Genetic Engineering | 35 | 2022 | 933 | 5.830 |
Why?
|
| Occupational Exposure | 55 | 2020 | 1805 | 5.600 |
Why?
|
| Gene Regulatory Networks | 44 | 2024 | 1749 | 5.090 |
Why?
|
| Bacteria | 32 | 2024 | 2209 | 4.970 |
Why?
|
| Chemical Industry | 33 | 2018 | 115 | 4.040 |
Why?
|
| Helminth Proteins | 10 | 2021 | 173 | 4.020 |
Why?
|
| Drug Resistance, Bacterial | 15 | 2022 | 1069 | 3.150 |
Why?
|
| Styrene | 7 | 2020 | 23 | 3.070 |
Why?
|
| Planarians | 10 | 2024 | 56 | 2.830 |
Why?
|
| Systems Biology | 15 | 2020 | 481 | 2.810 |
Why?
|
| Occupational Diseases | 33 | 2020 | 1456 | 2.750 |
Why?
|
| Microbial Viability | 14 | 2021 | 235 | 2.710 |
Why?
|
| Schistosomiasis mansoni | 7 | 2020 | 94 | 2.700 |
Why?
|
| Models, Genetic | 31 | 2016 | 3448 | 2.360 |
Why?
|
| Biosensing Techniques | 9 | 2024 | 642 | 2.130 |
Why?
|
| Dioxins | 10 | 2016 | 91 | 2.090 |
Why?
|
| Bacterial Physiological Phenomena | 7 | 2020 | 119 | 2.010 |
Why?
|
| Drug Discovery | 8 | 2023 | 1064 | 2.000 |
Why?
|
| Microbial Sensitivity Tests | 20 | 2024 | 1971 | 1.950 |
Why?
|
| Schistosoma | 4 | 2023 | 17 | 1.820 |
Why?
|
| Gene Expression Regulation, Bacterial | 20 | 2020 | 1141 | 1.820 |
Why?
|
| Saccharomyces cerevisiae | 16 | 2024 | 2674 | 1.810 |
Why?
|
| Chlorophenols | 8 | 2012 | 17 | 1.710 |
Why?
|
| Gene Expression Regulation | 36 | 2023 | 11888 | 1.640 |
Why?
|
| Escherichia coli Proteins | 16 | 2022 | 1057 | 1.560 |
Why?
|
| Transcription, Genetic | 27 | 2024 | 7599 | 1.550 |
Why?
|
| Acrylonitrile | 12 | 2012 | 19 | 1.540 |
Why?
|
| Biofilms | 10 | 2024 | 641 | 1.480 |
Why?
|
| Drug Resistance, Microbial | 6 | 2014 | 833 | 1.480 |
Why?
|
| Gene Expression Regulation, Fungal | 7 | 2024 | 494 | 1.430 |
Why?
|
| Postural Balance | 14 | 2006 | 637 | 1.370 |
Why?
|
| Carcinogens | 13 | 2018 | 452 | 1.360 |
Why?
|
| Genes, Synthetic | 7 | 2019 | 88 | 1.340 |
Why?
|
| Computational Biology | 18 | 2024 | 3559 | 1.330 |
Why?
|
| Bacterial Infections | 8 | 2018 | 1387 | 1.310 |
Why?
|
| Ampicillin | 6 | 2022 | 138 | 1.280 |
Why?
|
| Leukemia | 8 | 2015 | 1522 | 1.270 |
Why?
|
| Posture | 15 | 2017 | 954 | 1.270 |
Why?
|
| Animals | 165 | 2024 | 168759 | 1.250 |
Why?
|
| RNA | 14 | 2024 | 2717 | 1.250 |
Why?
|
| Genetic Techniques | 4 | 2020 | 429 | 1.240 |
Why?
|
| Escherichia coli Infections | 7 | 2021 | 519 | 1.240 |
Why?
|
| Anthelmintics | 4 | 2023 | 83 | 1.230 |
Why?
|
| Diagnostic Techniques and Procedures | 2 | 2020 | 216 | 1.220 |
Why?
|
| Accidents, Occupational | 4 | 2024 | 251 | 1.210 |
Why?
|
| Genome, Bacterial | 8 | 2022 | 797 | 1.210 |
Why?
|
| Plasmids | 10 | 2022 | 2274 | 1.200 |
Why?
|
| DNA, Bacterial | 8 | 2018 | 1477 | 1.200 |
Why?
|
| Schistosomiasis | 5 | 2024 | 65 | 1.190 |
Why?
|
| Pluripotent Stem Cells | 7 | 2017 | 807 | 1.180 |
Why?
|
| Protein Biosynthesis | 7 | 2021 | 2086 | 1.170 |
Why?
|
| Pathology, Molecular | 3 | 2020 | 330 | 1.170 |
Why?
|
| Bioengineering | 4 | 2012 | 97 | 1.160 |
Why?
|
| Platyhelminths | 2 | 2018 | 13 | 1.150 |
Why?
|
| Stem Cells | 10 | 2020 | 3540 | 1.140 |
Why?
|
| Stochastic Processes | 23 | 2016 | 358 | 1.120 |
Why?
|
| Benzofurans | 4 | 2009 | 140 | 1.110 |
Why?
|
| Containment of Biohazards | 2 | 2018 | 39 | 1.100 |
Why?
|
| Norfloxacin | 5 | 2015 | 24 | 1.100 |
Why?
|
| Kanamycin | 4 | 2015 | 63 | 1.090 |
Why?
|
| Formaldehyde | 9 | 2010 | 352 | 1.070 |
Why?
|
| Carbon | 4 | 2022 | 677 | 1.050 |
Why?
|
| Parasites | 3 | 2022 | 159 | 1.040 |
Why?
|
| Nucleic Acid Conformation | 4 | 2024 | 901 | 1.030 |
Why?
|
| Reactive Oxygen Species | 10 | 2024 | 2140 | 1.020 |
Why?
|
| Benzene | 6 | 2015 | 106 | 1.000 |
Why?
|
| Drug Tolerance | 3 | 2019 | 363 | 1.000 |
Why?
|
| Bacteriophages | 3 | 2015 | 381 | 0.960 |
Why?
|
| Gram-Negative Bacteria | 2 | 2019 | 275 | 0.950 |
Why?
|
| Cell Physiological Phenomena | 3 | 2018 | 148 | 0.950 |
Why?
|
| Bacterial Proteins | 14 | 2024 | 3837 | 0.940 |
Why?
|
| Clostridium Infections | 2 | 2024 | 564 | 0.920 |
Why?
|
| Adult Stem Cells | 3 | 2017 | 221 | 0.920 |
Why?
|
| Feces | 9 | 2024 | 1504 | 0.920 |
Why?
|
| Oxidative Stress | 10 | 2017 | 3141 | 0.910 |
Why?
|
| Host-Parasite Interactions | 2 | 2017 | 302 | 0.910 |
Why?
|
| Models, Biological | 29 | 2018 | 9443 | 0.910 |
Why?
|
| Peritonitis | 2 | 2017 | 369 | 0.900 |
Why?
|
| Aptamers, Nucleotide | 2 | 2024 | 163 | 0.890 |
Why?
|
| Toluene 2,4-Diisocyanate | 3 | 2017 | 13 | 0.890 |
Why?
|
| Communicable Diseases | 2 | 2023 | 874 | 0.890 |
Why?
|
| Lactococcus lactis | 3 | 2018 | 28 | 0.880 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2016 | 348 | 0.870 |
Why?
|
| Riboswitch | 2 | 2020 | 13 | 0.850 |
Why?
|
| RNA Interference | 12 | 2020 | 2832 | 0.850 |
Why?
|
| DNA Damage | 11 | 2024 | 2457 | 0.840 |
Why?
|
| DNA | 10 | 2022 | 7202 | 0.840 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 5 | 2024 | 592 | 0.840 |
Why?
|
| Protein Engineering | 6 | 2025 | 550 | 0.830 |
Why?
|
| Citric Acid Cycle | 4 | 2021 | 228 | 0.830 |
Why?
|
| Guanidines | 1 | 2023 | 194 | 0.820 |
Why?
|
| Muscular Dystrophies | 6 | 2017 | 392 | 0.820 |
Why?
|
| Nucleic Acids | 3 | 2023 | 193 | 0.820 |
Why?
|
| Genomics | 12 | 2023 | 5929 | 0.800 |
Why?
|
| Genes, Bacterial | 6 | 2021 | 1077 | 0.800 |
Why?
|
| Candida albicans | 2 | 2017 | 377 | 0.790 |
Why?
|
| Promoter Regions, Genetic | 14 | 2017 | 5786 | 0.790 |
Why?
|
| Amdinocillin | 1 | 2022 | 7 | 0.790 |
Why?
|
| Cause of Death | 24 | 2018 | 3708 | 0.790 |
Why?
|
| Humans | 342 | 2025 | 765956 | 0.790 |
Why?
|
| RNA Editing | 2 | 2023 | 148 | 0.780 |
Why?
|
| Signal Transduction | 26 | 2025 | 23600 | 0.780 |
Why?
|
| Pentachlorophenol | 5 | 2009 | 10 | 0.780 |
Why?
|
| Chromatin | 5 | 2024 | 2980 | 0.770 |
Why?
|
| Gene Expression | 10 | 2020 | 7584 | 0.770 |
Why?
|
| Endodeoxyribonucleases | 2 | 2020 | 165 | 0.760 |
Why?
|
| Transcriptional Activation | 6 | 2015 | 1744 | 0.760 |
Why?
|
| Pheromones | 1 | 2022 | 93 | 0.760 |
Why?
|
| Staining and Labeling | 2 | 2020 | 1072 | 0.760 |
Why?
|
| Green Fluorescent Proteins | 8 | 2018 | 2060 | 0.750 |
Why?
|
| Salmonella typhimurium | 2 | 2013 | 348 | 0.730 |
Why?
|
| RNA Processing, Post-Transcriptional | 3 | 2012 | 394 | 0.730 |
Why?
|
| Enterococcus faecium | 1 | 2022 | 101 | 0.730 |
Why?
|
| Air Pollutants, Occupational | 7 | 2017 | 406 | 0.720 |
Why?
|
| Genome | 5 | 2018 | 1753 | 0.720 |
Why?
|
| Paper | 2 | 2018 | 80 | 0.720 |
Why?
|
| DNA Transposable Elements | 2 | 2023 | 765 | 0.720 |
Why?
|
| Caenorhabditis elegans | 10 | 2022 | 1477 | 0.720 |
Why?
|
| Basic Reproduction Number | 1 | 2020 | 38 | 0.720 |
Why?
|
| Germ Cells | 4 | 2017 | 647 | 0.710 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2022 | 152 | 0.710 |
Why?
|
| Transcription Factors | 18 | 2024 | 12131 | 0.710 |
Why?
|
| Anilides | 1 | 2023 | 415 | 0.700 |
Why?
|
| Polychlorinated Biphenyls | 5 | 2014 | 234 | 0.700 |
Why?
|
| Aminoglycosides | 4 | 2021 | 161 | 0.700 |
Why?
|
| Operon | 2 | 2021 | 371 | 0.700 |
Why?
|
| Engineering | 2 | 2023 | 55 | 0.700 |
Why?
|
| Gene Expression Regulation, Developmental | 8 | 2017 | 3606 | 0.700 |
Why?
|
| Mice | 69 | 2024 | 81818 | 0.690 |
Why?
|
| Blood | 2 | 2020 | 597 | 0.690 |
Why?
|
| Eukaryotic Cells | 4 | 2013 | 192 | 0.690 |
Why?
|
| Accidental Falls | 6 | 2024 | 1078 | 0.680 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2020 | 126 | 0.680 |
Why?
|
| Quinolones | 5 | 2017 | 387 | 0.680 |
Why?
|
| Staphylococcus aureus | 7 | 2023 | 1424 | 0.670 |
Why?
|
| RNA, Messenger | 17 | 2021 | 12769 | 0.670 |
Why?
|
| Oxidation-Reduction | 6 | 2016 | 2218 | 0.670 |
Why?
|
| Catalase | 2 | 2024 | 216 | 0.670 |
Why?
|
| Life Cycle Stages | 3 | 2021 | 161 | 0.660 |
Why?
|
| Thiadiazoles | 1 | 2020 | 64 | 0.660 |
Why?
|
| Cell Respiration | 2 | 2017 | 197 | 0.660 |
Why?
|
| Organisms, Genetically Modified | 2 | 2018 | 63 | 0.660 |
Why?
|
| Biosynthetic Pathways | 1 | 2020 | 138 | 0.660 |
Why?
|
| Multigene Family | 2 | 2020 | 1080 | 0.650 |
Why?
|
| Collagen Type VI | 6 | 2017 | 26 | 0.650 |
Why?
|
| RNA, Bacterial | 6 | 2014 | 392 | 0.640 |
Why?
|
| Micronucleus Tests | 1 | 2018 | 23 | 0.630 |
Why?
|
| Oxygen Consumption | 3 | 2015 | 1870 | 0.620 |
Why?
|
| Musa | 1 | 2018 | 8 | 0.620 |
Why?
|
| Biological Evolution | 3 | 2022 | 1072 | 0.620 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 335 | 0.610 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2018 | 36 | 0.610 |
Why?
|
| Gene Expression Profiling | 20 | 2020 | 9524 | 0.610 |
Why?
|
| Gram-Positive Bacteria | 1 | 2019 | 180 | 0.610 |
Why?
|
| Cefuroxime | 7 | 1996 | 23 | 0.600 |
Why?
|
| Aging | 15 | 2023 | 8731 | 0.580 |
Why?
|
| Cell-Free System | 2 | 2016 | 339 | 0.580 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2020 | 576 | 0.570 |
Why?
|
| Plasmodium | 1 | 2020 | 248 | 0.570 |
Why?
|
| Population Surveillance | 5 | 2017 | 2590 | 0.560 |
Why?
|
| Lymphoma | 3 | 2014 | 1897 | 0.560 |
Why?
|
| Hydroxyl Radical | 5 | 2013 | 83 | 0.560 |
Why?
|
| Metabolome | 4 | 2017 | 1005 | 0.560 |
Why?
|
| Cell Membrane | 6 | 2021 | 3633 | 0.560 |
Why?
|
| Saccharomyces cerevisiae Proteins | 7 | 2024 | 1833 | 0.560 |
Why?
|
| Occupational Health | 7 | 2024 | 813 | 0.550 |
Why?
|
| Opportunistic Infections | 1 | 2020 | 376 | 0.550 |
Why?
|
| Probiotics | 3 | 2018 | 387 | 0.550 |
Why?
|
| Neoplasms | 31 | 2021 | 22340 | 0.550 |
Why?
|
| RNA, Untranslated | 2 | 2015 | 453 | 0.550 |
Why?
|
| Laminin | 5 | 2017 | 404 | 0.550 |
Why?
|
| Enzymes | 1 | 2018 | 254 | 0.540 |
Why?
|
| Mutation | 27 | 2022 | 30196 | 0.540 |
Why?
|
| Carrier State | 1 | 2020 | 529 | 0.540 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 856 | 0.540 |
Why?
|
| Molecular Biology | 3 | 2021 | 574 | 0.540 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2019 | 798 | 0.540 |
Why?
|
| Proteins | 5 | 2022 | 5995 | 0.540 |
Why?
|
| Algorithms | 14 | 2023 | 14071 | 0.530 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2017 | 1276 | 0.530 |
Why?
|
| Vitellins | 1 | 2016 | 1 | 0.530 |
Why?
|
| Cell Differentiation | 24 | 2023 | 11640 | 0.530 |
Why?
|
| Cytoplasm | 1 | 2021 | 1500 | 0.530 |
Why?
|
| Lactobacillus | 3 | 2018 | 213 | 0.530 |
Why?
|
| Computer Simulation | 13 | 2024 | 6255 | 0.530 |
Why?
|
| Biotechnology | 4 | 2018 | 284 | 0.520 |
Why?
|
| Repressor Proteins | 12 | 2018 | 2968 | 0.520 |
Why?
|
| Anti-Infective Agents | 2 | 2023 | 986 | 0.520 |
Why?
|
| Malaria | 3 | 2024 | 1246 | 0.510 |
Why?
|
| Esophagus | 2 | 2021 | 1037 | 0.500 |
Why?
|
| Benchmarking | 1 | 2022 | 1052 | 0.500 |
Why?
|
| Epigenomics | 2 | 2021 | 959 | 0.500 |
Why?
|
| Proprioception | 6 | 2003 | 133 | 0.500 |
Why?
|
| Environmental Pollutants | 5 | 2009 | 1291 | 0.500 |
Why?
|
| Gait | 8 | 2000 | 820 | 0.500 |
Why?
|
| Mutagenesis | 5 | 2018 | 1228 | 0.490 |
Why?
|
| Species Specificity | 9 | 2019 | 2406 | 0.490 |
Why?
|
| Retinal Pigments | 1 | 2015 | 81 | 0.490 |
Why?
|
| Epigenesis, Genetic | 8 | 2020 | 3819 | 0.490 |
Why?
|
| Metagenome | 4 | 2013 | 464 | 0.490 |
Why?
|
| Toxins, Biological | 1 | 2015 | 60 | 0.490 |
Why?
|
| Ocular Physiological Phenomena | 1 | 2015 | 67 | 0.480 |
Why?
|
| Military Personnel | 1 | 2024 | 1252 | 0.480 |
Why?
|
| Embryonic Stem Cells | 8 | 2020 | 1241 | 0.480 |
Why?
|
| Vinyl Chloride | 1 | 2014 | 15 | 0.480 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2015 | 93 | 0.480 |
Why?
|
| Mammals | 6 | 2023 | 1125 | 0.480 |
Why?
|
| RNA, Catalytic | 2 | 2012 | 52 | 0.470 |
Why?
|
| Zinc Fingers | 3 | 2015 | 576 | 0.470 |
Why?
|
| Muscular Dystrophy, Duchenne | 4 | 2022 | 271 | 0.470 |
Why?
|
| MutS DNA Mismatch-Binding Protein | 1 | 2014 | 10 | 0.460 |
Why?
|
| 2,4,5-Trichlorophenoxyacetic Acid | 3 | 2009 | 15 | 0.460 |
Why?
|
| Touch | 3 | 2003 | 309 | 0.460 |
Why?
|
| Genome, Viral | 2 | 2020 | 670 | 0.460 |
Why?
|
| Male | 167 | 2024 | 363691 | 0.450 |
Why?
|
| Parasitology | 2 | 2011 | 28 | 0.450 |
Why?
|
| Michigan | 8 | 2015 | 328 | 0.450 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 1774 | 0.450 |
Why?
|
| Female | 159 | 2024 | 396101 | 0.450 |
Why?
|
| Mitochondria | 4 | 2017 | 3673 | 0.440 |
Why?
|
| Stress, Physiological | 4 | 2016 | 1402 | 0.440 |
Why?
|
| Polysaccharides | 1 | 2020 | 1016 | 0.440 |
Why?
|
| Heart Valve Prosthesis | 19 | 1998 | 1466 | 0.440 |
Why?
|
| Hydrogels | 1 | 2019 | 728 | 0.440 |
Why?
|
| Gene Dosage | 2 | 2016 | 1216 | 0.430 |
Why?
|
| Alanine | 2 | 2021 | 612 | 0.430 |
Why?
|
| Oxygen | 6 | 2017 | 4241 | 0.430 |
Why?
|
| Reproduction | 6 | 2024 | 641 | 0.430 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2015 | 265 | 0.430 |
Why?
|
| Prokaryotic Cells | 1 | 2013 | 53 | 0.420 |
Why?
|
| MicroRNAs | 9 | 2022 | 3785 | 0.420 |
Why?
|
| Respiratory Tract Neoplasms | 3 | 2006 | 56 | 0.420 |
Why?
|
| RNA, Viral | 6 | 2023 | 2864 | 0.420 |
Why?
|
| Melanins | 1 | 2015 | 293 | 0.420 |
Why?
|
| Hematopoietic Stem Cells | 8 | 2024 | 3401 | 0.410 |
Why?
|
| Biocompatible Materials | 2 | 2019 | 1682 | 0.410 |
Why?
|
| Histones | 4 | 2022 | 2584 | 0.410 |
Why?
|
| Superoxides | 2 | 2013 | 383 | 0.410 |
Why?
|
| Cell Culture Techniques | 3 | 2019 | 1652 | 0.410 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2022 | 2942 | 0.410 |
Why?
|
| Antibody Formation | 3 | 2016 | 1391 | 0.410 |
Why?
|
| Genes, Helminth | 4 | 2020 | 146 | 0.400 |
Why?
|
| Ethosuximide | 3 | 2008 | 9 | 0.400 |
Why?
|
| Silver | 1 | 2013 | 120 | 0.400 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 211 | 0.400 |
Why?
|
| Vestibule, Labyrinth | 3 | 2001 | 234 | 0.390 |
Why?
|
| Vaccines | 2 | 2021 | 841 | 0.390 |
Why?
|
| Vibrio cholerae | 1 | 2018 | 793 | 0.390 |
Why?
|
| Feedback, Physiological | 6 | 2021 | 480 | 0.390 |
Why?
|
| Single-Cell Analysis | 6 | 2021 | 2536 | 0.390 |
Why?
|
| Peptides | 3 | 2024 | 4331 | 0.390 |
Why?
|
| Ciprofloxacin | 3 | 2021 | 314 | 0.390 |
Why?
|
| Apoptosis | 6 | 2017 | 9514 | 0.390 |
Why?
|
| Pain, Intractable | 3 | 1999 | 132 | 0.380 |
Why?
|
| Cholera | 1 | 2018 | 754 | 0.380 |
Why?
|
| Diabetic Neuropathies | 3 | 2006 | 408 | 0.380 |
Why?
|
| Induced Pluripotent Stem Cells | 8 | 2023 | 1883 | 0.380 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2018 | 1376 | 0.380 |
Why?
|
| Inhalation Exposure | 4 | 2019 | 432 | 0.380 |
Why?
|
| Body Patterning | 1 | 2016 | 633 | 0.380 |
Why?
|
| Microbial Consortia | 2 | 2024 | 35 | 0.380 |
Why?
|
| Regeneration | 3 | 2017 | 1517 | 0.370 |
Why?
|
| Phosgene | 1 | 2011 | 2 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2822 | 0.370 |
Why?
|
| Hydrogen Sulfide | 2 | 2014 | 147 | 0.370 |
Why?
|
| Prodrugs | 5 | 1996 | 273 | 0.370 |
Why?
|
| Vestibular Nerve | 2 | 2002 | 101 | 0.370 |
Why?
|
| Gentamicins | 1 | 2012 | 244 | 0.370 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2013 | 239 | 0.370 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 618 | 0.370 |
Why?
|
| Agrochemicals | 2 | 2018 | 9 | 0.360 |
Why?
|
| Laboratories | 1 | 2014 | 462 | 0.360 |
Why?
|
| Cells | 3 | 2019 | 162 | 0.360 |
Why?
|
| Directed Molecular Evolution | 2 | 2023 | 167 | 0.360 |
Why?
|
| Mutagenesis, Insertional | 3 | 2023 | 661 | 0.350 |
Why?
|
| Cephalosporins | 3 | 1996 | 200 | 0.350 |
Why?
|
| Gene Silencing | 4 | 2018 | 1505 | 0.350 |
Why?
|
| Gene Transfer, Horizontal | 4 | 2018 | 148 | 0.350 |
Why?
|
| Acinetobacter baumannii | 2 | 2023 | 125 | 0.350 |
Why?
|
| Drug Delivery Systems | 2 | 2020 | 2207 | 0.340 |
Why?
|
| Mitral Valve | 14 | 1998 | 1476 | 0.340 |
Why?
|
| Ribonucleotides | 1 | 2010 | 114 | 0.340 |
Why?
|
| Neurons, Afferent | 4 | 2002 | 497 | 0.340 |
Why?
|
| Regulatory Elements, Transcriptional | 2 | 2020 | 184 | 0.340 |
Why?
|
| Sensory Receptor Cells | 2 | 2008 | 513 | 0.340 |
Why?
|
| Drug Therapy, Combination | 9 | 2020 | 6309 | 0.340 |
Why?
|
| Noise | 2 | 2002 | 296 | 0.330 |
Why?
|
| Disease Models, Animal | 12 | 2024 | 18294 | 0.330 |
Why?
|
| Coronary Artery Bypass | 18 | 1999 | 2186 | 0.330 |
Why?
|
| Peptide Hormones | 1 | 2010 | 133 | 0.330 |
Why?
|
| Acrylic Resins | 2 | 2020 | 131 | 0.330 |
Why?
|
| DNA-Binding Proteins | 11 | 2020 | 9601 | 0.330 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 2659 | 0.330 |
Why?
|
| Hydrogen Peroxide | 5 | 2014 | 743 | 0.330 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 1965 | 0.330 |
Why?
|
| Tissue Engineering | 1 | 2019 | 1855 | 0.320 |
Why?
|
| Luminescent Proteins | 4 | 2018 | 839 | 0.320 |
Why?
|
| History, 20th Century | 8 | 2014 | 2761 | 0.320 |
Why?
|
| Mitochondrial Myopathies | 1 | 2009 | 49 | 0.320 |
Why?
|
| Escherichia coli K12 | 1 | 2009 | 35 | 0.320 |
Why?
|
| Fungal Proteins | 3 | 2017 | 899 | 0.320 |
Why?
|
| Phenotype | 12 | 2023 | 16721 | 0.320 |
Why?
|
| Recombinases | 1 | 2009 | 70 | 0.320 |
Why?
|
| Thymidine Kinase | 1 | 2009 | 286 | 0.320 |
Why?
|
| Microscopy, Fluorescence | 5 | 2021 | 2627 | 0.310 |
Why?
|
| Anticonvulsants | 3 | 2008 | 1921 | 0.310 |
Why?
|
| Microbial Interactions | 3 | 2024 | 74 | 0.310 |
Why?
|
| Drug Design | 3 | 2020 | 1042 | 0.310 |
Why?
|
| Aminobiphenyl Compounds | 3 | 1999 | 5 | 0.310 |
Why?
|
| Base Sequence | 8 | 2020 | 12403 | 0.310 |
Why?
|
| Vaccines, Synthetic | 1 | 2011 | 621 | 0.310 |
Why?
|
| Fibrinogen | 1 | 2012 | 895 | 0.310 |
Why?
|
| Immunologic Factors | 1 | 2017 | 1587 | 0.300 |
Why?
|
| Mortality | 6 | 2018 | 2904 | 0.300 |
Why?
|
| United States | 40 | 2024 | 72898 | 0.300 |
Why?
|
| Biodiversity | 2 | 2015 | 346 | 0.300 |
Why?
|
| Molecular Sequence Data | 11 | 2014 | 17594 | 0.300 |
Why?
|
| Pancreatic Neoplasms | 3 | 2014 | 5444 | 0.300 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2009 | 162 | 0.300 |
Why?
|
| Muscle, Skeletal | 9 | 2018 | 4959 | 0.300 |
Why?
|
| Endogenous Retroviruses | 2 | 2022 | 112 | 0.300 |
Why?
|
| Muscle Proteins | 4 | 2020 | 1158 | 0.300 |
Why?
|
| Lifting | 3 | 2007 | 56 | 0.290 |
Why?
|
| Anaerobiosis | 2 | 2022 | 140 | 0.290 |
Why?
|
| Guanosine Tetraphosphate | 1 | 2007 | 11 | 0.290 |
Why?
|
| Employee Performance Appraisal | 2 | 2005 | 86 | 0.290 |
Why?
|
| Bacteriophage T3 | 1 | 2007 | 2 | 0.290 |
Why?
|
| Epidemiologic Studies | 4 | 2018 | 677 | 0.290 |
Why?
|
| Antifungal Agents | 1 | 2013 | 769 | 0.290 |
Why?
|
| Genes, Switch | 1 | 2007 | 48 | 0.290 |
Why?
|
| Walking | 8 | 2003 | 1198 | 0.290 |
Why?
|
| Dengue | 3 | 2022 | 257 | 0.290 |
Why?
|
| Absenteeism | 3 | 2007 | 246 | 0.290 |
Why?
|
| History, 21st Century | 5 | 2014 | 1574 | 0.280 |
Why?
|
| Industry | 4 | 2007 | 362 | 0.280 |
Why?
|
| Graft Rejection | 5 | 2020 | 4499 | 0.280 |
Why?
|
| High-Throughput Screening Assays | 3 | 2024 | 938 | 0.280 |
Why?
|
| Risk | 11 | 2018 | 9591 | 0.280 |
Why?
|
| Morphine | 3 | 1996 | 660 | 0.280 |
Why?
|
| Lung Neoplasms | 13 | 2019 | 13451 | 0.280 |
Why?
|
| Myopathies, Structural, Congenital | 2 | 2018 | 103 | 0.280 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 622 | 0.280 |
Why?
|
| In Situ Hybridization | 4 | 2020 | 1886 | 0.270 |
Why?
|
| Adult | 91 | 2024 | 223038 | 0.270 |
Why?
|
| Drug Interactions | 4 | 2021 | 1417 | 0.270 |
Why?
|
| Epidemiology | 2 | 2007 | 279 | 0.270 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2007 | 94 | 0.270 |
Why?
|
| Models, Theoretical | 7 | 2019 | 3564 | 0.270 |
Why?
|
| Indoles | 2 | 2012 | 1839 | 0.270 |
Why?
|
| Point-of-Care Systems | 3 | 2021 | 1217 | 0.270 |
Why?
|
| Time Factors | 28 | 2023 | 40065 | 0.270 |
Why?
|
| Transportation of Patients | 2 | 2007 | 178 | 0.260 |
Why?
|
| Viral Proteins | 6 | 2009 | 1797 | 0.260 |
Why?
|
| Sensation Disorders | 2 | 2006 | 160 | 0.260 |
Why?
|
| Cell Proliferation | 6 | 2019 | 10429 | 0.260 |
Why?
|
| Logic | 3 | 2019 | 38 | 0.260 |
Why?
|
| Glutaral | 1 | 2006 | 76 | 0.260 |
Why?
|
| DNA Methylation | 3 | 2016 | 4424 | 0.260 |
Why?
|
| Carbohydrates | 1 | 2008 | 386 | 0.260 |
Why?
|
| Nanotechnology | 3 | 2024 | 703 | 0.250 |
Why?
|
| Cell Membrane Permeability | 2 | 2021 | 562 | 0.250 |
Why?
|
| Infant, Low Birth Weight | 1 | 2011 | 871 | 0.250 |
Why?
|
| Bacteriophage T7 | 1 | 2007 | 174 | 0.250 |
Why?
|
| Genes, tat | 1 | 2005 | 15 | 0.250 |
Why?
|
| Fluorescent Dyes | 4 | 2024 | 1930 | 0.250 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2014 | 3796 | 0.250 |
Why?
|
| Feedback | 5 | 2002 | 796 | 0.250 |
Why?
|
| Lab-On-A-Chip Devices | 3 | 2022 | 426 | 0.250 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2024 | 644 | 0.250 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2024 | 1917 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 11 | 2024 | 22331 | 0.250 |
Why?
|
| Environmental Exposure | 8 | 2019 | 4543 | 0.250 |
Why?
|
| Piracetam | 1 | 2006 | 88 | 0.250 |
Why?
|
| Virulence | 2 | 2020 | 1289 | 0.240 |
Why?
|
| Ecosystem | 3 | 2023 | 488 | 0.240 |
Why?
|
| Ribosomal Proteins | 1 | 2007 | 366 | 0.240 |
Why?
|
| Hydroxyurea | 3 | 2014 | 284 | 0.240 |
Why?
|
| Gene Knockdown Techniques | 3 | 2021 | 1599 | 0.240 |
Why?
|
| Lac Repressors | 3 | 2016 | 15 | 0.240 |
Why?
|
| Vibration | 2 | 2006 | 334 | 0.240 |
Why?
|
| Amino Acid Sequence | 7 | 2018 | 13400 | 0.240 |
Why?
|
| Amikacin | 1 | 2024 | 48 | 0.240 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2019 | 610 | 0.240 |
Why?
|
| Symbiosis | 2 | 2020 | 297 | 0.240 |
Why?
|
| Enzyme Inhibitors | 4 | 2014 | 3715 | 0.240 |
Why?
|
| Forecasting | 5 | 2021 | 2936 | 0.240 |
Why?
|
| Brain Neoplasms | 6 | 2014 | 9071 | 0.230 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2015 | 1403 | 0.230 |
Why?
|
| Gene Library | 3 | 2023 | 1067 | 0.230 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2024 | 220 | 0.230 |
Why?
|
| Genes, Regulator | 2 | 2003 | 373 | 0.230 |
Why?
|
| Amino Acids | 3 | 2024 | 1709 | 0.230 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 2 | 2017 | 185 | 0.230 |
Why?
|
| Genes, Reporter | 5 | 2020 | 1524 | 0.230 |
Why?
|
| Movement | 4 | 2019 | 1462 | 0.230 |
Why?
|
| New Zealand | 5 | 2018 | 359 | 0.230 |
Why?
|
| Extracellular Matrix | 2 | 2013 | 1727 | 0.230 |
Why?
|
| Ligands | 4 | 2022 | 3273 | 0.230 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 1188 | 0.230 |
Why?
|
| Vibrio | 1 | 2004 | 40 | 0.220 |
Why?
|
| Pregnancy Outcome | 3 | 2019 | 2967 | 0.220 |
Why?
|
| DNA, Mitochondrial | 1 | 2009 | 869 | 0.220 |
Why?
|
| Folic Acid Antagonists | 1 | 2024 | 75 | 0.220 |
Why?
|
| Bacteriuria | 1 | 2024 | 102 | 0.220 |
Why?
|
| Polyhydroxyalkanoates | 1 | 2023 | 5 | 0.220 |
Why?
|
| Knee Joint | 7 | 2002 | 1656 | 0.220 |
Why?
|
| Middle Aged | 82 | 2024 | 223004 | 0.220 |
Why?
|
| Endonucleases | 2 | 2018 | 372 | 0.220 |
Why?
|
| Locomotion | 2 | 1999 | 384 | 0.220 |
Why?
|
| Incidence | 19 | 2020 | 21480 | 0.220 |
Why?
|
| Risk Management | 1 | 2007 | 559 | 0.210 |
Why?
|
| Microfluidics | 2 | 2023 | 651 | 0.210 |
Why?
|
| Gene Deletion | 4 | 2019 | 2666 | 0.210 |
Why?
|
| Muscle Relaxation | 1 | 2003 | 138 | 0.210 |
Why?
|
| Hydrazones | 1 | 2023 | 105 | 0.210 |
Why?
|
| Metabolomics | 3 | 2017 | 1668 | 0.210 |
Why?
|
| Oxidants | 2 | 2014 | 166 | 0.210 |
Why?
|
| Shoes | 1 | 2003 | 90 | 0.210 |
Why?
|
| Cat Diseases | 1 | 2022 | 32 | 0.210 |
Why?
|
| Registries | 5 | 2014 | 8297 | 0.210 |
Why?
|
| Mitral Valve Insufficiency | 8 | 1998 | 1414 | 0.210 |
Why?
|
| Glucose | 1 | 2015 | 4335 | 0.210 |
Why?
|
| Trans-Activators | 4 | 2016 | 2850 | 0.210 |
Why?
|
| Periodicity | 3 | 2002 | 345 | 0.200 |
Why?
|
| Models, Statistical | 7 | 2021 | 5089 | 0.200 |
Why?
|
| Water Pollutants, Chemical | 2 | 2020 | 358 | 0.200 |
Why?
|
| Peptide Biosynthesis, Nucleic Acid-Independent | 1 | 2022 | 7 | 0.200 |
Why?
|
| Somatosensory Disorders | 1 | 2002 | 49 | 0.200 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 852 | 0.200 |
Why?
|
| Aerobiosis | 2 | 2013 | 99 | 0.200 |
Why?
|
| Anthozoa | 1 | 2023 | 65 | 0.200 |
Why?
|
| Herbicides | 3 | 2011 | 104 | 0.200 |
Why?
|
| Ligaments, Articular | 3 | 1995 | 306 | 0.200 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2005 | 435 | 0.200 |
Why?
|
| Mitral Valve Prolapse | 2 | 1994 | 213 | 0.190 |
Why?
|
| Genes | 2 | 2003 | 1825 | 0.190 |
Why?
|
| Dog Diseases | 1 | 2022 | 142 | 0.190 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2020 | 2505 | 0.190 |
Why?
|
| Rec A Recombinases | 3 | 2012 | 50 | 0.190 |
Why?
|
| Adenine | 2 | 2019 | 994 | 0.190 |
Why?
|
| Tryptamines | 1 | 2022 | 94 | 0.190 |
Why?
|
| Adenosine Triphosphate | 3 | 2015 | 1999 | 0.190 |
Why?
|
| Viral Regulatory and Accessory Proteins | 4 | 2005 | 151 | 0.190 |
Why?
|
| Cell Lineage | 7 | 2019 | 2573 | 0.190 |
Why?
|
| Genes, Fungal | 1 | 2003 | 441 | 0.190 |
Why?
|
| Linear Models | 5 | 2018 | 5876 | 0.190 |
Why?
|
| Textiles | 1 | 2021 | 43 | 0.190 |
Why?
|
| Chikungunya virus | 1 | 2022 | 54 | 0.190 |
Why?
|
| Carbenicillin | 1 | 2021 | 12 | 0.190 |
Why?
|
| Bioprosthesis | 6 | 1998 | 589 | 0.190 |
Why?
|
| Sarcoma | 6 | 2018 | 1802 | 0.190 |
Why?
|
| K562 Cells | 2 | 2020 | 649 | 0.190 |
Why?
|
| Foot | 5 | 2003 | 573 | 0.190 |
Why?
|
| Hypesthesia | 1 | 2002 | 106 | 0.190 |
Why?
|
| Liver Neoplasms | 3 | 2014 | 4353 | 0.190 |
Why?
|
| Musculoskeletal System | 1 | 2003 | 187 | 0.190 |
Why?
|
| HEK293 Cells | 7 | 2025 | 4258 | 0.190 |
Why?
|
| Electricity | 1 | 2002 | 174 | 0.190 |
Why?
|
| Ketoglutarate Dehydrogenase Complex | 1 | 2021 | 20 | 0.180 |
Why?
|
| Streptomycin | 1 | 2021 | 70 | 0.180 |
Why?
|
| Aged | 66 | 2017 | 171114 | 0.180 |
Why?
|
| Tumor Virus Infections | 3 | 2020 | 440 | 0.180 |
Why?
|
| Cohort Studies | 26 | 2018 | 41647 | 0.180 |
Why?
|
| Drug Synergism | 3 | 2021 | 1749 | 0.180 |
Why?
|
| Infant, Premature | 1 | 2011 | 2122 | 0.180 |
Why?
|
| Equipment and Supplies | 1 | 2003 | 273 | 0.180 |
Why?
|
| Regression Analysis | 8 | 2011 | 6321 | 0.180 |
Why?
|
| Premature Birth | 2 | 2011 | 1829 | 0.180 |
Why?
|
| Ribosomes | 1 | 2004 | 493 | 0.180 |
Why?
|
| Mathematics | 7 | 2003 | 696 | 0.180 |
Why?
|
| Teratogens | 1 | 2001 | 121 | 0.180 |
Why?
|
| Pseudomonas fluorescens | 1 | 2020 | 22 | 0.180 |
Why?
|
| Adenosine Deaminase | 1 | 2023 | 251 | 0.180 |
Why?
|
| Dystrophin | 1 | 2022 | 283 | 0.180 |
Why?
|
| Teaching | 2 | 2018 | 1169 | 0.180 |
Why?
|
| Nonlinear Dynamics | 6 | 2013 | 490 | 0.180 |
Why?
|
| Labor, Obstetric | 1 | 2023 | 316 | 0.170 |
Why?
|
| Phylogeny | 3 | 2018 | 2832 | 0.170 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2002 | 170 | 0.170 |
Why?
|
| Microscopy, Atomic Force | 1 | 2021 | 250 | 0.170 |
Why?
|
| Staphylococcal Infections | 4 | 2023 | 1393 | 0.170 |
Why?
|
| Phalloidine | 1 | 2020 | 21 | 0.170 |
Why?
|
| Sensation | 1 | 2002 | 331 | 0.170 |
Why?
|
| Cercaria | 1 | 2019 | 1 | 0.170 |
Why?
|
| Rotifera | 1 | 2019 | 3 | 0.170 |
Why?
|
| Membrane Proteins | 4 | 2017 | 7851 | 0.170 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 4772 | 0.170 |
Why?
|
| Sequence Deletion | 2 | 2022 | 1495 | 0.170 |
Why?
|
| Chemokine CXCL9 | 1 | 2020 | 137 | 0.170 |
Why?
|
| Environmental Illness | 1 | 2000 | 33 | 0.170 |
Why?
|
| Aged, 80 and over | 35 | 2014 | 59488 | 0.170 |
Why?
|
| beta-Lactamases | 1 | 2022 | 308 | 0.170 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 136 | 0.170 |
Why?
|
| Neurons | 7 | 2015 | 9524 | 0.170 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2024 | 632 | 0.170 |
Why?
|
| Cell Division | 3 | 2014 | 4475 | 0.160 |
Why?
|
| Bone Marrow | 2 | 2024 | 2921 | 0.160 |
Why?
|
| Microbiological Techniques | 1 | 2020 | 96 | 0.160 |
Why?
|
| Bacterial Capsules | 1 | 2020 | 246 | 0.160 |
Why?
|
| Adolescent | 36 | 2017 | 88832 | 0.160 |
Why?
|
| Electric Stimulation | 5 | 2003 | 1735 | 0.160 |
Why?
|
| Parthenogenesis | 1 | 2019 | 29 | 0.160 |
Why?
|
| Nerve Net | 5 | 2003 | 2310 | 0.160 |
Why?
|
| Occupational Medicine | 1 | 2000 | 116 | 0.160 |
Why?
|
| Models, Neurological | 2 | 1999 | 1747 | 0.160 |
Why?
|
| Kinetics | 4 | 2020 | 6274 | 0.160 |
Why?
|
| DNA Cleavage | 1 | 2019 | 56 | 0.160 |
Why?
|
| Polyomavirus | 1 | 2020 | 236 | 0.160 |
Why?
|
| Muscular Diseases | 2 | 2013 | 550 | 0.160 |
Why?
|
| Mechanoreceptors | 2 | 2001 | 193 | 0.160 |
Why?
|
| Protein Binding | 4 | 2022 | 9296 | 0.160 |
Why?
|
| Atlases as Topic | 1 | 2020 | 247 | 0.160 |
Why?
|
| Haploidy | 1 | 2019 | 128 | 0.160 |
Why?
|
| Solvents | 2 | 1997 | 299 | 0.160 |
Why?
|
| Temperature | 6 | 2023 | 2226 | 0.160 |
Why?
|
| Fluoroquinolones | 1 | 2021 | 307 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2021 | 3737 | 0.160 |
Why?
|
| Thermodynamics | 1 | 2020 | 580 | 0.160 |
Why?
|
| Transgenes | 2 | 2022 | 1015 | 0.160 |
Why?
|
| Statistics as Topic | 5 | 2002 | 2352 | 0.160 |
Why?
|
| Colic | 1 | 2018 | 42 | 0.150 |
Why?
|
| Information Dissemination | 1 | 2007 | 1142 | 0.150 |
Why?
|
| TATA Box | 2 | 2010 | 127 | 0.150 |
Why?
|
| Alternative Splicing | 2 | 2014 | 1107 | 0.150 |
Why?
|
| Follow-Up Studies | 23 | 2013 | 39194 | 0.150 |
Why?
|
| Dengue Virus | 2 | 2018 | 202 | 0.150 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2001 | 335 | 0.150 |
Why?
|
| Alkaloids | 1 | 2019 | 190 | 0.150 |
Why?
|
| Oxidative Phosphorylation | 2 | 2017 | 502 | 0.150 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2018 | 2745 | 0.150 |
Why?
|
| Forced Expiratory Volume | 3 | 2017 | 1828 | 0.150 |
Why?
|
| Ovum | 1 | 2019 | 187 | 0.150 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2018 | 92 | 0.150 |
Why?
|
| Palliative Care | 4 | 1998 | 3645 | 0.150 |
Why?
|
| Muscle Strength | 2 | 2020 | 637 | 0.150 |
Why?
|
| Gastrointestinal Tract | 2 | 2014 | 834 | 0.150 |
Why?
|
| Parkinson Disease | 4 | 2014 | 2895 | 0.150 |
Why?
|
| Arabinose | 2 | 2009 | 31 | 0.150 |
Why?
|
| Sulfhydryl Compounds | 1 | 1999 | 296 | 0.150 |
Why?
|
| Spinal Cord | 2 | 1999 | 1784 | 0.150 |
Why?
|
| Home Nursing | 1 | 1998 | 91 | 0.150 |
Why?
|
| Polyomavirus Infections | 1 | 2020 | 194 | 0.150 |
Why?
|
| Codon, Terminator | 1 | 2018 | 125 | 0.150 |
Why?
|
| Paneth Cells | 1 | 2018 | 99 | 0.140 |
Why?
|
| Analgesics, Opioid | 4 | 1999 | 3835 | 0.140 |
Why?
|
| Growth Substances | 1 | 2020 | 758 | 0.140 |
Why?
|
| Risk Factors | 24 | 2024 | 74836 | 0.140 |
Why?
|
| Dextrans | 1 | 2020 | 571 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2022 | 691 | 0.140 |
Why?
|
| Disease Susceptibility | 1 | 2024 | 1789 | 0.140 |
Why?
|
| Tuberous Sclerosis | 1 | 2006 | 1038 | 0.140 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 2 | 2011 | 24 | 0.140 |
Why?
|
| Cells, Cultured | 13 | 2023 | 18973 | 0.140 |
Why?
|
| Small Molecule Libraries | 2 | 2020 | 741 | 0.140 |
Why?
|
| Energy Metabolism | 2 | 2021 | 2892 | 0.140 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2018 | 1043 | 0.140 |
Why?
|
| Sexual Maturation | 1 | 2019 | 246 | 0.140 |
Why?
|
| Guidelines as Topic | 3 | 2019 | 1394 | 0.140 |
Why?
|
| DNA, Single-Stranded | 1 | 2019 | 353 | 0.140 |
Why?
|
| RNA-Binding Proteins | 2 | 2016 | 1874 | 0.140 |
Why?
|
| Leg | 2 | 1995 | 1080 | 0.140 |
Why?
|
| Population Dynamics | 1 | 2019 | 314 | 0.140 |
Why?
|
| Nanoparticles | 3 | 2020 | 1964 | 0.140 |
Why?
|
| Ultraviolet Rays | 1 | 2022 | 1102 | 0.140 |
Why?
|
| DNA, Superhelical | 1 | 2017 | 52 | 0.140 |
Why?
|
| Permeability | 1 | 2019 | 726 | 0.140 |
Why?
|
| Cloning, Molecular | 2 | 2020 | 4165 | 0.140 |
Why?
|
| Carcinogens, Environmental | 1 | 1997 | 70 | 0.140 |
Why?
|
| Antimalarials | 1 | 2024 | 913 | 0.140 |
Why?
|
| Enzyme Assays | 1 | 2018 | 102 | 0.140 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 705 | 0.140 |
Why?
|
| Leukemia, Experimental | 3 | 1983 | 225 | 0.140 |
Why?
|
| Fluconazole | 1 | 2017 | 154 | 0.140 |
Why?
|
| RNA, Antisense | 1 | 2017 | 135 | 0.140 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2005 | 1957 | 0.140 |
Why?
|
| Immune Evasion | 1 | 2020 | 377 | 0.140 |
Why?
|
| Genes, Lethal | 1 | 2017 | 224 | 0.140 |
Why?
|
| Aortic Aneurysm | 4 | 1997 | 623 | 0.140 |
Why?
|
| DNA, Fungal | 1 | 2018 | 276 | 0.140 |
Why?
|
| Euthanasia | 1 | 1997 | 58 | 0.140 |
Why?
|
| Quorum Sensing | 1 | 2018 | 137 | 0.140 |
Why?
|
| Obstetric Labor Complications | 1 | 2019 | 240 | 0.140 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2020 | 2476 | 0.140 |
Why?
|
| Child | 30 | 2020 | 80563 | 0.140 |
Why?
|
| Terminal Care | 4 | 1997 | 1774 | 0.140 |
Why?
|
| Arthrogryposis | 1 | 2017 | 70 | 0.130 |
Why?
|
| Plants | 2 | 2015 | 331 | 0.130 |
Why?
|
| Immunoassay | 1 | 2020 | 741 | 0.130 |
Why?
|
| Stomach Ulcer | 1 | 2016 | 118 | 0.130 |
Why?
|
| CCAAT-Binding Factor | 1 | 2016 | 21 | 0.130 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 605 | 0.130 |
Why?
|
| DNA Replication | 3 | 2014 | 1433 | 0.130 |
Why?
|
| Spermatogonia | 1 | 2016 | 30 | 0.130 |
Why?
|
| Ribonucleases | 1 | 2017 | 265 | 0.130 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2010 | 296 | 0.130 |
Why?
|
| Cyclins | 1 | 1998 | 598 | 0.130 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2024 | 942 | 0.130 |
Why?
|
| Fishes | 1 | 1999 | 606 | 0.130 |
Why?
|
| Antigens, Helminth | 1 | 2016 | 67 | 0.130 |
Why?
|
| Hydromorphone | 1 | 1996 | 70 | 0.130 |
Why?
|
| Cross-Linking Reagents | 1 | 2019 | 687 | 0.130 |
Why?
|
| Pregnancy Complications | 2 | 2019 | 2971 | 0.130 |
Why?
|
| Clavulanic Acids | 4 | 1996 | 11 | 0.130 |
Why?
|
| Flow Cytometry | 5 | 2019 | 5881 | 0.130 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1996 | 117 | 0.130 |
Why?
|
| Myography | 1 | 2017 | 111 | 0.130 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2016 | 136 | 0.130 |
Why?
|
| Antitubercular Agents | 1 | 2024 | 1384 | 0.130 |
Why?
|
| RNA, Helminth | 1 | 2016 | 60 | 0.130 |
Why?
|
| Cell Death | 2 | 2014 | 1679 | 0.130 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2014 | 498 | 0.130 |
Why?
|
| Receptors, Erythropoietin | 1 | 2016 | 145 | 0.130 |
Why?
|
| Sequence Alignment | 2 | 2010 | 2171 | 0.130 |
Why?
|
| Blood Vessel Prosthesis | 4 | 1996 | 912 | 0.130 |
Why?
|
| Peristalsis | 1 | 2015 | 60 | 0.130 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 4 | 1996 | 32 | 0.130 |
Why?
|
| Ascorbic Acid | 1 | 2019 | 657 | 0.130 |
Why?
|
| Research | 3 | 2014 | 1975 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2009 | 1165 | 0.130 |
Why?
|
| Malaria, Falciparum | 1 | 2024 | 1075 | 0.120 |
Why?
|
| Purines | 1 | 2019 | 615 | 0.120 |
Why?
|
| Embryo, Nonmammalian | 1 | 2019 | 907 | 0.120 |
Why?
|
| Body Height | 2 | 2020 | 1562 | 0.120 |
Why?
|
| 5-Hydroxytryptophan | 1 | 2015 | 33 | 0.120 |
Why?
|
| Longevity | 3 | 2008 | 1087 | 0.120 |
Why?
|
| Skin | 4 | 2023 | 4489 | 0.120 |
Why?
|
| Environmental Monitoring | 5 | 2017 | 1470 | 0.120 |
Why?
|
| Bronchitis | 2 | 1995 | 193 | 0.120 |
Why?
|
| Motor Skills | 1 | 1998 | 516 | 0.120 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 751 | 0.120 |
Why?
|
| Muscular Dystrophy, Emery-Dreifuss | 1 | 2015 | 21 | 0.120 |
Why?
|
| Texas | 2 | 2008 | 410 | 0.120 |
Why?
|
| Fentanyl | 1 | 1999 | 457 | 0.120 |
Why?
|
| Lymphocyte Activation | 5 | 2025 | 5501 | 0.120 |
Why?
|
| Skin Physiological Phenomena | 1 | 1996 | 193 | 0.120 |
Why?
|
| Confidence Intervals | 8 | 2010 | 2910 | 0.120 |
Why?
|
| Hypogravity | 1 | 1995 | 3 | 0.120 |
Why?
|
| Entomoplasmataceae | 1 | 2014 | 1 | 0.120 |
Why?
|
| Rats | 15 | 2022 | 23707 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 8611 | 0.120 |
Why?
|
| Amitriptyline | 1 | 1995 | 109 | 0.120 |
Why?
|
| Survival Rate | 16 | 2008 | 12795 | 0.120 |
Why?
|
| Spermatogenesis | 1 | 2016 | 260 | 0.120 |
Why?
|
| Periaqueductal Gray | 1 | 1995 | 111 | 0.120 |
Why?
|
| Epidermis | 1 | 2018 | 538 | 0.120 |
Why?
|
| Aortic Valve | 13 | 1998 | 1968 | 0.120 |
Why?
|
| Oncogene Proteins | 2 | 2016 | 710 | 0.120 |
Why?
|
| Plectin | 1 | 2014 | 14 | 0.120 |
Why?
|
| Epidermolysis Bullosa Simplex | 1 | 2014 | 12 | 0.120 |
Why?
|
| Alcohol Dehydrogenase | 1 | 1995 | 113 | 0.120 |
Why?
|
| DNA, Viral | 2 | 2020 | 2199 | 0.120 |
Why?
|
| Caenorhabditis elegans Proteins | 2 | 2008 | 884 | 0.120 |
Why?
|
| Sequence Analysis, RNA | 3 | 2018 | 2035 | 0.120 |
Why?
|
| Zebrafish | 3 | 2022 | 3035 | 0.120 |
Why?
|
| Psychomotor Performance | 1 | 2003 | 1881 | 0.120 |
Why?
|
| Green Chemistry Technology | 1 | 2014 | 10 | 0.120 |
Why?
|
| Amoxicillin | 4 | 1996 | 180 | 0.120 |
Why?
|
| Lymphopenia | 1 | 1997 | 297 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2021 | 3458 | 0.120 |
Why?
|
| Joints | 2 | 2000 | 321 | 0.110 |
Why?
|
| Amino Acids, Essential | 1 | 2014 | 26 | 0.110 |
Why?
|
| Substrate Specificity | 2 | 2023 | 1752 | 0.110 |
Why?
|
| Otitis Media with Effusion | 1 | 1995 | 115 | 0.110 |
Why?
|
| Collagen Type XII | 1 | 2013 | 3 | 0.110 |
Why?
|
| Urinary Tract Infections | 3 | 2024 | 805 | 0.110 |
Why?
|
| Host Factor 1 Protein | 1 | 2014 | 15 | 0.110 |
Why?
|
| Hematopoiesis | 3 | 2024 | 2058 | 0.110 |
Why?
|
| Theophylline | 3 | 1988 | 132 | 0.110 |
Why?
|
| Fibroblasts | 5 | 2023 | 4159 | 0.110 |
Why?
|
| RGS Proteins | 1 | 2014 | 75 | 0.110 |
Why?
|
| Public Health | 2 | 2023 | 2680 | 0.110 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2016 | 507 | 0.110 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 1308 | 0.110 |
Why?
|
| Cell Line | 5 | 2020 | 15543 | 0.110 |
Why?
|
| Age Factors | 14 | 2017 | 18380 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 1333 | 0.110 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2014 | 91 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 3 | 2020 | 6220 | 0.110 |
Why?
|
| Death Certificates | 1 | 2014 | 170 | 0.110 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 2014 | 89 | 0.110 |
Why?
|
| Proviruses | 1 | 2015 | 319 | 0.110 |
Why?
|
| Nurses | 1 | 2003 | 2505 | 0.110 |
Why?
|
| Peer Group | 1 | 2019 | 701 | 0.110 |
Why?
|
| Perceptual Masking | 2 | 2006 | 90 | 0.110 |
Why?
|
| Phosphorylation | 1 | 2025 | 8278 | 0.110 |
Why?
|
| Epidemiologic Methods | 5 | 2007 | 1326 | 0.110 |
Why?
|
| Risk Assessment | 11 | 2019 | 24283 | 0.110 |
Why?
|
| United States Occupational Safety and Health Administration | 2 | 2023 | 54 | 0.110 |
Why?
|
| Metalloproteins | 1 | 2014 | 98 | 0.110 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 798 | 0.110 |
Why?
|
| Young Adult | 10 | 2024 | 59886 | 0.110 |
Why?
|
| Environment | 2 | 2017 | 1114 | 0.110 |
Why?
|
| Otitis Media | 1 | 1996 | 287 | 0.110 |
Why?
|
| Klebsiella pneumoniae | 2 | 2024 | 253 | 0.110 |
Why?
|
| Mesencephalon | 1 | 1995 | 338 | 0.110 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2015 | 604 | 0.110 |
Why?
|
| Rhabdoid Tumor | 1 | 1995 | 209 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 836 | 0.110 |
Why?
|
| West Virginia | 2 | 2006 | 32 | 0.110 |
Why?
|
| Efficiency, Organizational | 1 | 2018 | 697 | 0.110 |
Why?
|
| Miconazole | 1 | 2013 | 9 | 0.110 |
Why?
|
| Weight Lifting | 1 | 1994 | 130 | 0.110 |
Why?
|
| Praziquantel | 2 | 2023 | 34 | 0.110 |
Why?
|
| Mucous Membrane | 1 | 1996 | 657 | 0.110 |
Why?
|
| Physical Stimulation | 3 | 2003 | 513 | 0.110 |
Why?
|
| Host Specificity | 1 | 2013 | 56 | 0.100 |
Why?
|
| Iron | 3 | 2013 | 1816 | 0.100 |
Why?
|
| Severity of Illness Index | 7 | 2017 | 15880 | 0.100 |
Why?
|
| Body Mass Index | 4 | 2017 | 13039 | 0.100 |
Why?
|
| Genomic Instability | 1 | 2017 | 718 | 0.100 |
Why?
|
| Prostatic Neoplasms | 4 | 2007 | 11083 | 0.100 |
Why?
|
| Bronchial Hyperreactivity | 1 | 1994 | 300 | 0.100 |
Why?
|
| Erythrocytes | 2 | 2019 | 2395 | 0.100 |
Why?
|
| Ureaplasma Infections | 1 | 2012 | 25 | 0.100 |
Why?
|
| Ureaplasma | 1 | 2012 | 59 | 0.100 |
Why?
|
| Allergens | 1 | 2020 | 1436 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 1996 | 318 | 0.100 |
Why?
|
| Biomimetics | 1 | 2014 | 168 | 0.100 |
Why?
|
| Postoperative Complications | 19 | 2020 | 15747 | 0.100 |
Why?
|
| Coronary Disease | 7 | 1995 | 5912 | 0.100 |
Why?
|
| Muscles | 3 | 1996 | 1578 | 0.100 |
Why?
|
| Pregnenediones | 1 | 2012 | 29 | 0.100 |
Why?
|
| Antioxidants | 2 | 2014 | 1670 | 0.100 |
Why?
|
| Homozygote | 1 | 2017 | 1775 | 0.100 |
Why?
|
| Seizures | 1 | 2006 | 3000 | 0.100 |
Why?
|
| Anesthesia, Conduction | 1 | 1996 | 264 | 0.100 |
Why?
|
| Amphotericin B | 1 | 2013 | 140 | 0.100 |
Why?
|
| Child, Preschool | 16 | 2018 | 42500 | 0.100 |
Why?
|
| Sensory Thresholds | 3 | 2002 | 377 | 0.100 |
Why?
|
| Helminthiasis | 1 | 2013 | 81 | 0.100 |
Why?
|
| Maternal Exposure | 2 | 2011 | 1096 | 0.100 |
Why?
|
| Immunization, Passive | 5 | 1983 | 616 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2019 | 10729 | 0.100 |
Why?
|
| Electric Impedance | 1 | 2017 | 794 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 12509 | 0.100 |
Why?
|
| Muscle Contraction | 2 | 1995 | 1206 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 6493 | 0.100 |
Why?
|
| Communication | 2 | 2018 | 3916 | 0.100 |
Why?
|
| Guanine Nucleotides | 1 | 2012 | 54 | 0.100 |
Why?
|
| Endopeptidase Clp | 1 | 2012 | 42 | 0.100 |
Why?
|
| Bacterial Toxins | 2 | 2015 | 924 | 0.100 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2013 | 192 | 0.100 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 780 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2002 | 2966 | 0.100 |
Why?
|
| Electron Transport | 1 | 2013 | 210 | 0.100 |
Why?
|
| Retrospective Studies | 22 | 2019 | 81515 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 1936 | 0.100 |
Why?
|
| Multipotent Stem Cells | 1 | 2013 | 199 | 0.100 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2018 | 845 | 0.100 |
Why?
|
| Erythropoiesis | 3 | 2024 | 691 | 0.100 |
Why?
|
| Odds Ratio | 6 | 2017 | 9649 | 0.100 |
Why?
|
| Genes, Viral | 1 | 2013 | 654 | 0.100 |
Why?
|
| Ebolavirus | 1 | 2014 | 250 | 0.100 |
Why?
|
| Organoids | 1 | 2018 | 739 | 0.100 |
Why?
|
| Space Flight | 1 | 1995 | 219 | 0.100 |
Why?
|
| Pandemics | 2 | 2023 | 8701 | 0.100 |
Why?
|
| Adhesins, Bacterial | 1 | 2012 | 118 | 0.100 |
Why?
|
| DNA Restriction Enzymes | 1 | 2012 | 548 | 0.100 |
Why?
|
| Ultrasonic Therapy | 1 | 1994 | 216 | 0.100 |
Why?
|
| Phagocytosis | 1 | 2017 | 1520 | 0.100 |
Why?
|
| DNA Fragmentation | 1 | 2012 | 238 | 0.100 |
Why?
|
| Disorders of Sex Development | 1 | 2013 | 129 | 0.100 |
Why?
|
| Genetic Code | 1 | 2012 | 139 | 0.100 |
Why?
|
| Motor Neurons | 2 | 1999 | 869 | 0.100 |
Why?
|
| Testis | 2 | 2014 | 780 | 0.090 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 14749 | 0.090 |
Why?
|
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 2011 | 22 | 0.090 |
Why?
|
| beta-Lactams | 1 | 2013 | 158 | 0.090 |
Why?
|
| Administration, Inhalation | 4 | 2008 | 1154 | 0.090 |
Why?
|
| Erythropoietin | 1 | 2016 | 716 | 0.090 |
Why?
|
| Proton-Motive Force | 1 | 2011 | 8 | 0.090 |
Why?
|
| Gene Amplification | 1 | 2016 | 1091 | 0.090 |
Why?
|
| Databases, Factual | 4 | 2019 | 8067 | 0.090 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 359 | 0.090 |
Why?
|
| Automation | 1 | 2014 | 585 | 0.090 |
Why?
|
| Genetic Association Studies | 3 | 2018 | 2741 | 0.090 |
Why?
|
| Heart Valves | 1 | 1993 | 284 | 0.090 |
Why?
|
| Chorioamnionitis | 1 | 2012 | 155 | 0.090 |
Why?
|
| Soil Pollutants | 1 | 2012 | 80 | 0.090 |
Why?
|
| Natural Language Processing | 1 | 2020 | 1203 | 0.090 |
Why?
|
| DNA, Helminth | 1 | 2011 | 36 | 0.090 |
Why?
|
| Biological Clocks | 1 | 1994 | 320 | 0.090 |
Why?
|
| Upper Extremity | 1 | 2016 | 682 | 0.090 |
Why?
|
| Antigens, Viral | 4 | 1978 | 995 | 0.090 |
Why?
|
| Animal Structures | 1 | 2011 | 25 | 0.090 |
Why?
|
| Central Nervous System | 1 | 1998 | 1341 | 0.090 |
Why?
|
| RNA, Small Interfering | 3 | 2016 | 3421 | 0.090 |
Why?
|
| Melanoma | 3 | 2021 | 5719 | 0.090 |
Why?
|
| Reproducibility of Results | 8 | 2014 | 20125 | 0.090 |
Why?
|
| Cell Cycle Proteins | 2 | 2022 | 3430 | 0.090 |
Why?
|
| Disulfides | 1 | 2013 | 462 | 0.090 |
Why?
|
| Eye | 1 | 2015 | 710 | 0.090 |
Why?
|
| Friend murine leukemia virus | 5 | 1983 | 37 | 0.090 |
Why?
|
| Safety Management | 2 | 2007 | 763 | 0.090 |
Why?
|
| Anabolic Agents | 1 | 2013 | 256 | 0.090 |
Why?
|
| Chromosomes, Bacterial | 1 | 2012 | 281 | 0.090 |
Why?
|
| Culicidae | 1 | 2011 | 110 | 0.090 |
Why?
|
| Biological Products | 1 | 2020 | 942 | 0.090 |
Why?
|
| Phosphatidylserines | 1 | 2012 | 184 | 0.090 |
Why?
|
| North America | 1 | 2014 | 1285 | 0.090 |
Why?
|
| Birth Certificates | 1 | 2011 | 71 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 1999 | 2176 | 0.090 |
Why?
|
| Guanine | 1 | 2012 | 282 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1510 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2003 | 2511 | 0.090 |
Why?
|
| Treatment Outcome | 17 | 2024 | 65189 | 0.090 |
Why?
|
| Genes, Recessive | 1 | 2013 | 624 | 0.090 |
Why?
|
| Insect Vectors | 1 | 2011 | 136 | 0.090 |
Why?
|
| Electromyography | 4 | 2003 | 1399 | 0.090 |
Why?
|
| Radiography, Interventional | 1 | 2018 | 1129 | 0.090 |
Why?
|
| Bioreactors | 1 | 2012 | 244 | 0.090 |
Why?
|
| Homeostasis | 1 | 2022 | 3336 | 0.090 |
Why?
|
| Peptide Elongation Factors | 1 | 2010 | 59 | 0.090 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 5783 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 13648 | 0.090 |
Why?
|
| Platelet Aggregation | 2 | 2012 | 769 | 0.090 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2013 | 484 | 0.090 |
Why?
|
| Acrylamide | 2 | 2007 | 59 | 0.090 |
Why?
|
| Analgesia | 1 | 1995 | 461 | 0.090 |
Why?
|
| Cell Cycle | 1 | 1998 | 2920 | 0.090 |
Why?
|
| Trimethadione | 2 | 2008 | 2 | 0.090 |
Why?
|
| Rifamycins | 1 | 2010 | 27 | 0.090 |
Why?
|
| Erythrocyte Indices | 1 | 1991 | 145 | 0.090 |
Why?
|
| DNA-Directed RNA Polymerases | 2 | 2010 | 368 | 0.090 |
Why?
|
| Serotonin | 1 | 2015 | 1047 | 0.090 |
Why?
|
| Dystroglycans | 1 | 2010 | 62 | 0.090 |
Why?
|
| Neuropeptides | 1 | 2016 | 951 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2005 | 9347 | 0.090 |
Why?
|
| Octamer Transcription Factor-3 | 3 | 2017 | 220 | 0.090 |
Why?
|
| Biofuels | 1 | 2010 | 45 | 0.090 |
Why?
|
| Blood Cell Count | 1 | 1991 | 405 | 0.090 |
Why?
|
| Pain | 4 | 2000 | 5077 | 0.080 |
Why?
|
| Nerve Regeneration | 1 | 2016 | 802 | 0.080 |
Why?
|
| Inflammation | 3 | 2018 | 10850 | 0.080 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2010 | 109 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 1994 | 415 | 0.080 |
Why?
|
| Ovary | 1 | 2014 | 956 | 0.080 |
Why?
|
| Cholesterol | 1 | 2019 | 2898 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 1811 | 0.080 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2016 | 3645 | 0.080 |
Why?
|
| Pregnancy | 9 | 2023 | 30258 | 0.080 |
Why?
|
| Technology, Pharmaceutical | 1 | 2010 | 83 | 0.080 |
Why?
|
| Genetic Testing | 2 | 2020 | 3595 | 0.080 |
Why?
|
| Bioelectric Energy Sources | 1 | 2009 | 15 | 0.080 |
Why?
|
| Integrin alpha Chains | 1 | 2010 | 93 | 0.080 |
Why?
|
| Survival Analysis | 10 | 2009 | 10070 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 634 | 0.080 |
Why?
|
| Flocculation | 1 | 2009 | 3 | 0.080 |
Why?
|
| Scotoma | 1 | 1990 | 128 | 0.080 |
Why?
|
| Reoperation | 13 | 1997 | 4294 | 0.080 |
Why?
|
| Cell Transplantation | 1 | 2011 | 473 | 0.080 |
Why?
|
| Infant | 11 | 2018 | 36385 | 0.080 |
Why?
|
| Fingers | 2 | 2003 | 509 | 0.080 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 1461 | 0.080 |
Why?
|
| HeLa Cells | 1 | 2015 | 3067 | 0.080 |
Why?
|
| Macaca mulatta | 1 | 2016 | 2341 | 0.080 |
Why?
|
| Head | 1 | 2015 | 925 | 0.080 |
Why?
|
| Neurosurgery | 1 | 1996 | 683 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2020 | 2098 | 0.080 |
Why?
|
| Methylmethacrylates | 1 | 1989 | 64 | 0.080 |
Why?
|
| Light | 1 | 2015 | 1364 | 0.080 |
Why?
|
| Caspases | 1 | 2012 | 880 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2021 | 3050 | 0.080 |
Why?
|
| Models, Molecular | 2 | 2024 | 5379 | 0.080 |
Why?
|
| Myocardial Ischemia | 2 | 2016 | 2128 | 0.080 |
Why?
|
| Interleukin-1 | 1 | 2012 | 1243 | 0.080 |
Why?
|
| Hematologic Tests | 1 | 2010 | 239 | 0.080 |
Why?
|
| Sequence Analysis, Protein | 1 | 2010 | 261 | 0.080 |
Why?
|
| Infant, Newborn | 7 | 2018 | 26349 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2012 | 561 | 0.080 |
Why?
|
| Sodium | 1 | 2014 | 1591 | 0.080 |
Why?
|
| Fibronectins | 1 | 2012 | 719 | 0.080 |
Why?
|
| Manufactured Materials | 1 | 2008 | 18 | 0.080 |
Why?
|
| Cross-Sectional Studies | 9 | 2017 | 26313 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 3750 | 0.080 |
Why?
|
| Protein Denaturation | 1 | 2008 | 240 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 10383 | 0.080 |
Why?
|
| Antigens, CD34 | 3 | 2019 | 656 | 0.080 |
Why?
|
| Analgesics | 1 | 1995 | 1060 | 0.080 |
Why?
|
| Colony Count, Microbial | 2 | 2007 | 326 | 0.080 |
Why?
|
| Stroke | 3 | 2006 | 9747 | 0.080 |
Why?
|
| Drug Resistance | 3 | 2022 | 1591 | 0.080 |
Why?
|
| Selenoproteins | 1 | 2010 | 216 | 0.070 |
Why?
|
| T-Lymphocytes | 3 | 2025 | 10261 | 0.070 |
Why?
|
| Dyneins | 1 | 2008 | 126 | 0.070 |
Why?
|
| Glucocorticoids | 2 | 2020 | 2132 | 0.070 |
Why?
|
| Pulmonary Edema | 1 | 2011 | 412 | 0.070 |
Why?
|
| Kidney | 3 | 2020 | 7066 | 0.070 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2007 | 9 | 0.070 |
Why?
|
| Neuroblastoma | 1 | 2016 | 1263 | 0.070 |
Why?
|
| Carbon-Sulfur Lyases | 1 | 2007 | 17 | 0.070 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2014 | 788 | 0.070 |
Why?
|
| Simian virus 40 | 3 | 1973 | 290 | 0.070 |
Why?
|
| Regenerative Medicine | 1 | 2011 | 303 | 0.070 |
Why?
|
| HIV-1 | 1 | 2005 | 6944 | 0.070 |
Why?
|
| Evolution, Molecular | 2 | 2014 | 1889 | 0.070 |
Why?
|
| Actuarial Analysis | 5 | 1998 | 366 | 0.070 |
Why?
|
| Actins | 1 | 2015 | 2056 | 0.070 |
Why?
|
| Ferrous Compounds | 1 | 2007 | 39 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 2 | 2010 | 2686 | 0.070 |
Why?
|
| Double-Blind Method | 6 | 2024 | 12437 | 0.070 |
Why?
|
| Homeodomain Proteins | 2 | 2014 | 2428 | 0.070 |
Why?
|
| ras Proteins | 1 | 2013 | 1053 | 0.070 |
Why?
|
| Growth Disorders | 1 | 2012 | 633 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2017 | 2395 | 0.070 |
Why?
|
| Molecular Epidemiology | 2 | 2017 | 471 | 0.070 |
Why?
|
| Human Growth Hormone | 1 | 2012 | 638 | 0.070 |
Why?
|
| Acrylamides | 1 | 1989 | 257 | 0.070 |
Why?
|
| Smoking | 6 | 2010 | 9081 | 0.070 |
Why?
|
| Pyridones | 1 | 2013 | 816 | 0.070 |
Why?
|
| Leukemia Virus, Murine | 2 | 1978 | 96 | 0.070 |
Why?
|
| Antibodies, Viral | 5 | 2022 | 3211 | 0.070 |
Why?
|
| Planning Techniques | 2 | 2000 | 81 | 0.070 |
Why?
|
| DNA Repair | 2 | 2014 | 2048 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 5891 | 0.070 |
Why?
|
| Intestinal Mucosa | 2 | 2015 | 3046 | 0.070 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2009 | 291 | 0.070 |
Why?
|
| Hip Joint | 3 | 2001 | 1000 | 0.070 |
Why?
|
| Keratinocytes | 1 | 2011 | 863 | 0.070 |
Why?
|
| Software | 4 | 2024 | 4462 | 0.070 |
Why?
|
| Health Education | 1 | 1994 | 1060 | 0.070 |
Why?
|
| Cell Wall | 1 | 2010 | 420 | 0.070 |
Why?
|
| Drosophila melanogaster | 1 | 2016 | 1721 | 0.070 |
Why?
|
| Intestines | 2 | 2012 | 1906 | 0.070 |
Why?
|
| Fertility Agents, Female | 1 | 2007 | 101 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2010 | 504 | 0.070 |
Why?
|
| Interneurons | 1 | 1992 | 593 | 0.070 |
Why?
|
| Tocotrienols | 1 | 2006 | 3 | 0.070 |
Why?
|
| Exercise Test | 2 | 2014 | 2180 | 0.070 |
Why?
|
| Cell Survival | 4 | 2021 | 5746 | 0.070 |
Why?
|
| Ginkgo biloba | 1 | 2006 | 26 | 0.070 |
Why?
|
| Health Status | 1 | 2000 | 4080 | 0.070 |
Why?
|
| Nitrogen Fixation | 1 | 1986 | 66 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 4 | 1999 | 3675 | 0.070 |
Why?
|
| Ethylenediamines | 1 | 2006 | 47 | 0.070 |
Why?
|
| Blindness | 1 | 1990 | 586 | 0.070 |
Why?
|
| Free Radical Scavengers | 1 | 2007 | 212 | 0.070 |
Why?
|
| Gestational Age | 2 | 2017 | 3613 | 0.070 |
Why?
|
| Body Weight | 6 | 2017 | 4622 | 0.070 |
Why?
|
| Furans | 1 | 2007 | 198 | 0.070 |
Why?
|
| Diphtheria Toxin | 1 | 2007 | 253 | 0.070 |
Why?
|
| Anemia | 1 | 2016 | 1511 | 0.070 |
Why?
|
| Isopropyl Thiogalactoside | 1 | 2006 | 11 | 0.070 |
Why?
|
| Iron Chelating Agents | 1 | 2007 | 142 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 1996 | 1543 | 0.070 |
Why?
|
| Protein Precursors | 1 | 2010 | 1134 | 0.070 |
Why?
|
| Visual Perception | 1 | 1995 | 1394 | 0.070 |
Why?
|
| Cardiomyopathies | 2 | 2014 | 2067 | 0.060 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2007 | 283 | 0.060 |
Why?
|
| Cricetinae | 3 | 2007 | 2411 | 0.060 |
Why?
|
| Models, Animal | 2 | 2010 | 2120 | 0.060 |
Why?
|
| Collagen | 2 | 2013 | 2618 | 0.060 |
Why?
|
| Cell Biology | 1 | 2007 | 91 | 0.060 |
Why?
|
| Salicylates | 1 | 2006 | 125 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2020 | 3985 | 0.060 |
Why?
|
| Nursing Staff | 1 | 2007 | 113 | 0.060 |
Why?
|
| Organizational Policy | 2 | 2007 | 434 | 0.060 |
Why?
|
| Job Description | 1 | 2006 | 61 | 0.060 |
Why?
|
| Case-Control Studies | 6 | 2018 | 22222 | 0.060 |
Why?
|
| Occupations | 1 | 2008 | 516 | 0.060 |
Why?
|
| Chemotaxis | 1 | 2008 | 596 | 0.060 |
Why?
|
| Stilbenes | 1 | 2006 | 154 | 0.060 |
Why?
|
| Cricetulus | 1 | 2007 | 805 | 0.060 |
Why?
|
| Prostate | 1 | 2013 | 1755 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 1992 | 1297 | 0.060 |
Why?
|
| Drug Administration Schedule | 5 | 1996 | 4850 | 0.060 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 17075 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2009 | 3537 | 0.060 |
Why?
|
| Anorexia | 1 | 2006 | 153 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 2045 | 0.060 |
Why?
|
| Analysis of Variance | 4 | 2004 | 6203 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2011 | 2652 | 0.060 |
Why?
|
| Ischemic Attack, Transient | 1 | 1990 | 870 | 0.060 |
Why?
|
| Recurrence | 4 | 2015 | 8501 | 0.060 |
Why?
|
| Valproic Acid | 1 | 2008 | 445 | 0.060 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2005 | 52 | 0.060 |
Why?
|
| Phenols | 1 | 2009 | 522 | 0.060 |
Why?
|
| Prosthesis Design | 4 | 2001 | 2105 | 0.060 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2006 | 355 | 0.060 |
Why?
|
| Ubiquinone | 1 | 2006 | 181 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 4270 | 0.060 |
Why?
|
| Integrases | 1 | 2007 | 520 | 0.060 |
Why?
|
| Fetal Blood | 1 | 2011 | 1369 | 0.060 |
Why?
|
| Infant Mortality | 1 | 2010 | 751 | 0.060 |
Why?
|
| Sensitivity and Specificity | 5 | 2021 | 14652 | 0.060 |
Why?
|
| Protein Folding | 1 | 2008 | 869 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 4392 | 0.060 |
Why?
|
| CHO Cells | 1 | 2007 | 1372 | 0.060 |
Why?
|
| Research Design | 3 | 2010 | 6208 | 0.060 |
Why?
|
| Cell Communication | 2 | 2022 | 1660 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 1761 | 0.060 |
Why?
|
| Sexual Development | 1 | 2024 | 37 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2012 | 1995 | 0.060 |
Why?
|
| Spirometry | 2 | 2017 | 929 | 0.060 |
Why?
|
| Galactosides | 1 | 2024 | 54 | 0.060 |
Why?
|
| Vital Capacity | 2 | 2017 | 995 | 0.060 |
Why?
|
| Diffusion | 2 | 2017 | 808 | 0.060 |
Why?
|
| Heart Ventricles | 3 | 2014 | 3832 | 0.060 |
Why?
|
| Epithelium | 1 | 2009 | 1599 | 0.060 |
Why?
|
| Biophysical Phenomena | 3 | 2017 | 318 | 0.060 |
Why?
|
| Peptide Synthases | 1 | 2024 | 81 | 0.060 |
Why?
|
| Mannitol | 1 | 2024 | 176 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2021 | 3111 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2008 | 1467 | 0.060 |
Why?
|
| Behavioral Symptoms | 1 | 2006 | 187 | 0.060 |
Why?
|
| Binding Sites | 2 | 2015 | 6001 | 0.060 |
Why?
|
| Publication Bias | 1 | 2004 | 158 | 0.060 |
Why?
|
| Causality | 2 | 2007 | 1248 | 0.060 |
Why?
|
| Switzerland | 1 | 2024 | 322 | 0.050 |
Why?
|
| Genetics | 1 | 2004 | 114 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 6069 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 1490 | 0.050 |
Why?
|
| Autophagy | 1 | 2011 | 1351 | 0.050 |
Why?
|
| Nitriles | 1 | 1989 | 982 | 0.050 |
Why?
|
| Hazardous Substances | 1 | 2004 | 153 | 0.050 |
Why?
|
| Thioredoxins | 1 | 2005 | 202 | 0.050 |
Why?
|
| Animals, Wild | 1 | 2023 | 78 | 0.050 |
Why?
|
| B-Lymphocytes | 2 | 2014 | 4778 | 0.050 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2006 | 246 | 0.050 |
Why?
|
| Muscle Weakness | 2 | 2018 | 413 | 0.050 |
Why?
|
| NAD | 1 | 2007 | 619 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 1857 | 0.050 |
Why?
|
| Fenbendazole | 1 | 2022 | 1 | 0.050 |
Why?
|
| Pyrantel Pamoate | 1 | 2022 | 1 | 0.050 |
Why?
|
| Ancylostomatoidea | 1 | 2022 | 5 | 0.050 |
Why?
|
| Ancylostoma | 1 | 2022 | 10 | 0.050 |
Why?
|
| Administration, Oral | 5 | 2008 | 4015 | 0.050 |
Why?
|
| Fetal Development | 1 | 2009 | 777 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2006 | 735 | 0.050 |
Why?
|
| Parasite Egg Count | 1 | 2022 | 29 | 0.050 |
Why?
|
| Heart Valve Diseases | 4 | 1999 | 1030 | 0.050 |
Why?
|
| Oceans and Seas | 1 | 2023 | 47 | 0.050 |
Why?
|
| Educational Status | 1 | 2011 | 2513 | 0.050 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 1992 | 1339 | 0.050 |
Why?
|
| Prenatal Care | 1 | 2011 | 1159 | 0.050 |
Why?
|
| Aortic Valve Stenosis | 3 | 1998 | 2023 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 330 | 0.050 |
Why?
|
| London | 1 | 2023 | 233 | 0.050 |
Why?
|
| Immunosorbents | 1 | 2022 | 21 | 0.050 |
Why?
|
| Nucleotides | 2 | 2016 | 451 | 0.050 |
Why?
|
| 5' Untranslated Regions | 1 | 2004 | 256 | 0.050 |
Why?
|
| Testosterone | 1 | 2013 | 2494 | 0.050 |
Why?
|
| Trachea | 1 | 2009 | 1085 | 0.050 |
Why?
|
| Coral Reefs | 1 | 2023 | 36 | 0.050 |
Why?
|
| Organometallic Compounds | 1 | 2006 | 644 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2018 | 3853 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2006 | 496 | 0.050 |
Why?
|
| Pain Measurement | 3 | 1999 | 3561 | 0.050 |
Why?
|
| Georgia | 1 | 2022 | 186 | 0.050 |
Why?
|
| Systems Theory | 1 | 2002 | 57 | 0.050 |
Why?
|
| Half-Life | 3 | 2014 | 644 | 0.050 |
Why?
|
| Mitomycin | 1 | 2003 | 261 | 0.050 |
Why?
|
| Binomial Distribution | 1 | 2002 | 23 | 0.050 |
Why?
|
| RNA, Fungal | 1 | 2003 | 156 | 0.050 |
Why?
|
| Splints | 1 | 2023 | 108 | 0.050 |
Why?
|
| Mesonephros | 1 | 2022 | 42 | 0.050 |
Why?
|
| Lentivirus | 1 | 2005 | 518 | 0.050 |
Why?
|
| Arthroscopy | 1 | 1989 | 966 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 11022 | 0.050 |
Why?
|
| Ankle Joint | 2 | 1998 | 450 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2013 | 2643 | 0.050 |
Why?
|
| Defoliants, Chemical | 1 | 2001 | 9 | 0.050 |
Why?
|
| DNA Probes | 1 | 2023 | 541 | 0.050 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2003 | 187 | 0.050 |
Why?
|
| Rats, Inbred F344 | 4 | 1992 | 822 | 0.050 |
Why?
|
| Burkholderia cepacia | 1 | 2002 | 22 | 0.050 |
Why?
|
| Lac Operon | 1 | 2002 | 238 | 0.050 |
Why?
|
| Vitamin E | 1 | 2006 | 869 | 0.050 |
Why?
|
| Hospitalization | 2 | 2019 | 10808 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2024 | 639 | 0.050 |
Why?
|
| bcl-Associated Death Protein | 1 | 2022 | 102 | 0.050 |
Why?
|
| Stress, Mechanical | 3 | 1996 | 1669 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 16047 | 0.050 |
Why?
|
| Immune Complex Diseases | 1 | 1981 | 50 | 0.050 |
Why?
|
| Reference Values | 5 | 2008 | 4908 | 0.050 |
Why?
|
| Macrolides | 1 | 2022 | 204 | 0.050 |
Why?
|
| Burkholderia Infections | 1 | 2002 | 41 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 2015 | 3404 | 0.050 |
Why?
|
| Mastoid | 1 | 2002 | 100 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2023 | 824 | 0.050 |
Why?
|
| Protein Isoforms | 2 | 2018 | 1718 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 5849 | 0.050 |
Why?
|
| Antibodies, Neoplasm | 2 | 1980 | 282 | 0.050 |
Why?
|
| Catalysis | 1 | 2023 | 770 | 0.050 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 1996 | 452 | 0.050 |
Why?
|
| Infertility, Female | 1 | 2007 | 763 | 0.050 |
Why?
|
| Protein Interaction Mapping | 1 | 2005 | 619 | 0.050 |
Why?
|
| Toxicity Tests | 1 | 2001 | 111 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 2429 | 0.050 |
Why?
|
| Bacteriophage lambda | 1 | 2001 | 142 | 0.050 |
Why?
|
| Workplace | 2 | 2006 | 873 | 0.050 |
Why?
|
| Inservice Training | 2 | 2018 | 375 | 0.050 |
Why?
|
| Hemodynamics | 6 | 1995 | 4183 | 0.040 |
Why?
|
| RNA Splice Sites | 1 | 2022 | 212 | 0.040 |
Why?
|
| 3' Untranslated Regions | 2 | 2016 | 515 | 0.040 |
Why?
|
| Calcium | 1 | 2014 | 5767 | 0.040 |
Why?
|
| Hematologic Neoplasms | 2 | 2004 | 1927 | 0.040 |
Why?
|
| Logistic Models | 5 | 2011 | 13266 | 0.040 |
Why?
|
| Musculoskeletal Diseases | 1 | 2006 | 598 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 1981 | 2844 | 0.040 |
Why?
|
| Sutures | 2 | 1994 | 284 | 0.040 |
Why?
|
| Freeze Drying | 1 | 2020 | 97 | 0.040 |
Why?
|
| Venoms | 1 | 2020 | 94 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2007 | 1088 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3608 | 0.040 |
Why?
|
| Doxycycline | 2 | 2012 | 349 | 0.040 |
Why?
|
| Netherlands | 4 | 2007 | 2277 | 0.040 |
Why?
|
| Pediatrics | 1 | 1995 | 3606 | 0.040 |
Why?
|
| Air Pollutants | 1 | 1994 | 2923 | 0.040 |
Why?
|
| Plankton | 1 | 1999 | 21 | 0.040 |
Why?
|
| Yeasts | 1 | 2001 | 278 | 0.040 |
Why?
|
| Prosthesis-Related Infections | 3 | 1995 | 496 | 0.040 |
Why?
|
| Erythroblasts | 1 | 2020 | 142 | 0.040 |
Why?
|
| Snails | 1 | 2019 | 21 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 231 | 0.040 |
Why?
|
| Rubber | 1 | 1999 | 32 | 0.040 |
Why?
|
| Contract Services | 1 | 2000 | 89 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2007 | 1509 | 0.040 |
Why?
|
| Learning | 1 | 2009 | 1755 | 0.040 |
Why?
|
| England | 2 | 2019 | 533 | 0.040 |
Why?
|
| Somatosensory Cortex | 1 | 2003 | 510 | 0.040 |
Why?
|
| Pressure | 3 | 1993 | 1168 | 0.040 |
Why?
|
| Endocarditis, Bacterial | 2 | 1994 | 434 | 0.040 |
Why?
|
| Glomerulonephritis | 1 | 1981 | 332 | 0.040 |
Why?
|
| Electrodes | 1 | 2002 | 609 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2010 | 4025 | 0.040 |
Why?
|
| Introns | 1 | 2022 | 966 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2004 | 966 | 0.040 |
Why?
|
| Microarray Analysis | 2 | 2012 | 752 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2011 | 1880 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2017 | 9550 | 0.040 |
Why?
|
| Plasma | 1 | 2022 | 579 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 5337 | 0.040 |
Why?
|
| Endometriosis | 1 | 2007 | 870 | 0.040 |
Why?
|
| Heart Transplantation | 5 | 1992 | 3310 | 0.040 |
Why?
|
| Peripheral Nerves | 1 | 2002 | 491 | 0.040 |
Why?
|
| Employment | 1 | 2005 | 1106 | 0.040 |
Why?
|
| Dust | 1 | 2001 | 489 | 0.040 |
Why?
|
| Acinetobacter | 1 | 2018 | 39 | 0.040 |
Why?
|
| New South Wales | 1 | 1998 | 69 | 0.040 |
Why?
|
| Games, Experimental | 1 | 1998 | 32 | 0.040 |
Why?
|
| Health Facilities | 1 | 2003 | 577 | 0.040 |
Why?
|
| Pedigree | 2 | 2017 | 4526 | 0.040 |
Why?
|
| Arteriosclerosis | 3 | 1997 | 1053 | 0.040 |
Why?
|
| Sentinel Surveillance | 1 | 2000 | 293 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2021 | 955 | 0.040 |
Why?
|
| Dogs | 2 | 2022 | 3822 | 0.040 |
Why?
|
| RecQ Helicases | 1 | 2018 | 54 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2011 | 8041 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2018 | 239 | 0.040 |
Why?
|
| Air Pollution | 2 | 2011 | 2380 | 0.040 |
Why?
|
| Policy Making | 1 | 2001 | 546 | 0.040 |
Why?
|
| Axillary Vein | 1 | 1997 | 16 | 0.040 |
Why?
|
| Northern Territory | 1 | 1997 | 5 | 0.040 |
Why?
|
| Commerce | 1 | 2023 | 611 | 0.040 |
Why?
|
| Solubility | 1 | 2019 | 1078 | 0.040 |
Why?
|
| Spleen | 1 | 2024 | 2296 | 0.040 |
Why?
|
| Fluorescence | 1 | 2020 | 753 | 0.040 |
Why?
|
| Proteomics | 3 | 2018 | 3910 | 0.040 |
Why?
|
| Axillary Artery | 1 | 1997 | 48 | 0.040 |
Why?
|
| Saliva | 1 | 2022 | 851 | 0.040 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2018 | 100 | 0.040 |
Why?
|
| Virus Replication | 1 | 2005 | 2447 | 0.040 |
Why?
|
| Acute Disease | 4 | 1996 | 7232 | 0.030 |
Why?
|
| Base Pairing | 1 | 2017 | 139 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2012 | 3459 | 0.030 |
Why?
|
| Spinal Nerve Roots | 1 | 2017 | 122 | 0.030 |
Why?
|
| Epilepsy | 1 | 2012 | 3320 | 0.030 |
Why?
|
| Muscle Spindles | 1 | 1996 | 15 | 0.030 |
Why?
|
| Nausea | 1 | 2000 | 680 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2022 | 722 | 0.030 |
Why?
|
| Boston | 6 | 1996 | 9338 | 0.030 |
Why?
|
| Pulmonary Atelectasis | 1 | 1998 | 161 | 0.030 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2017 | 100 | 0.030 |
Why?
|
| Infant Formula | 1 | 2018 | 192 | 0.030 |
Why?
|
| Referral and Consultation | 2 | 2017 | 3615 | 0.030 |
Why?
|
| Femoral Vein | 1 | 1997 | 157 | 0.030 |
Why?
|
| Age of Onset | 2 | 2015 | 3343 | 0.030 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2018 | 184 | 0.030 |
Why?
|
| Suicide, Assisted | 1 | 1997 | 68 | 0.030 |
Why?
|
| Embolism, Cholesterol | 1 | 1996 | 33 | 0.030 |
Why?
|
| Consanguinity | 1 | 2018 | 460 | 0.030 |
Why?
|
| Electrophysiology | 1 | 1999 | 1263 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 1999 | 715 | 0.030 |
Why?
|
| Genes, vpr | 1 | 2016 | 19 | 0.030 |
Why?
|
| Stomach Neoplasms | 2 | 2001 | 1471 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 3 | 1997 | 1090 | 0.030 |
Why?
|
| Fertility | 1 | 2001 | 768 | 0.030 |
Why?
|
| Therapeutic Equivalency | 1 | 1996 | 134 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2018 | 737 | 0.030 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2020 | 475 | 0.030 |
Why?
|
| Mice, Inbred DBA | 3 | 1983 | 623 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1999 | 675 | 0.030 |
Why?
|
| Data Collection | 2 | 1997 | 3318 | 0.030 |
Why?
|
| Abortion, Spontaneous | 1 | 2001 | 536 | 0.030 |
Why?
|
| Endocardial Cushion Defects | 1 | 1996 | 43 | 0.030 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2006 | 1090 | 0.030 |
Why?
|
| Suspensions | 1 | 1996 | 66 | 0.030 |
Why?
|
| Biopsy | 2 | 2018 | 6763 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 2845 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 4893 | 0.030 |
Why?
|
| Climate Change | 1 | 2023 | 509 | 0.030 |
Why?
|
| Maternal Age | 1 | 2019 | 804 | 0.030 |
Why?
|
| Methods | 2 | 1994 | 1052 | 0.030 |
Why?
|
| Subarachnoid Space | 1 | 1996 | 77 | 0.030 |
Why?
|
| Cardioplegic Solutions | 1 | 1996 | 123 | 0.030 |
Why?
|
| Sleep Stages | 1 | 2000 | 698 | 0.030 |
Why?
|
| Cough | 1 | 2000 | 597 | 0.030 |
Why?
|
| Therapy, Computer-Assisted | 1 | 1998 | 265 | 0.030 |
Why?
|
| Ganglia | 1 | 2016 | 86 | 0.030 |
Why?
|
| Embryonal Carcinoma Stem Cells | 1 | 2015 | 20 | 0.030 |
Why?
|
| Hemostasis, Surgical | 1 | 1996 | 127 | 0.030 |
Why?
|
| Chromatin Assembly Factor-1 | 1 | 2015 | 21 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2003 | 1429 | 0.030 |
Why?
|
| Metal Nanoparticles | 1 | 2020 | 403 | 0.030 |
Why?
|
| Metals | 1 | 2020 | 710 | 0.030 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2017 | 282 | 0.030 |
Why?
|
| Rifampin | 1 | 2018 | 351 | 0.030 |
Why?
|
| Genetic Variation | 2 | 2018 | 6610 | 0.030 |
Why?
|
| Ileus | 1 | 2015 | 65 | 0.030 |
Why?
|
| Prostheses and Implants | 2 | 1994 | 1273 | 0.030 |
Why?
|
| Mice, Nude | 3 | 2012 | 3618 | 0.030 |
Why?
|
| Australia | 1 | 2019 | 1258 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 1999 | 5302 | 0.030 |
Why?
|
| Equipment Design | 1 | 2003 | 3481 | 0.030 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2015 | 68 | 0.030 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 2210 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2021 | 2077 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2014 | 8733 | 0.030 |
Why?
|
| Prospective Studies | 9 | 1999 | 54806 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 2014 | 0.030 |
Why?
|
| Thromboembolism | 4 | 1998 | 1003 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2015 | 366 | 0.030 |
Why?
|
| Immunity | 2 | 1978 | 1002 | 0.030 |
Why?
|
| Intraoperative Care | 2 | 1996 | 760 | 0.030 |
Why?
|
| Regulatory Sequences, Ribonucleic Acid | 1 | 2014 | 29 | 0.030 |
Why?
|
| Sex Factors | 6 | 1992 | 10602 | 0.030 |
Why?
|
| Myopathies, Nemaline | 1 | 2015 | 73 | 0.030 |
Why?
|
| Surgical Staplers | 2 | 1992 | 34 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 1995 | 395 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2018 | 1160 | 0.030 |
Why?
|
| Glutathione | 1 | 2017 | 588 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2018 | 346 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2018 | 820 | 0.030 |
Why?
|
| Weight Loss | 1 | 2006 | 2710 | 0.030 |
Why?
|
| Heart Arrest, Induced | 1 | 1996 | 358 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1999 | 772 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 20660 | 0.030 |
Why?
|
| Volatilization | 1 | 1994 | 75 | 0.030 |
Why?
|
| Calcinosis | 3 | 1994 | 1479 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2017 | 506 | 0.030 |
Why?
|
| Acetamides | 1 | 1996 | 260 | 0.030 |
Why?
|
| Ribotyping | 1 | 2014 | 35 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 370 | 0.030 |
Why?
|
| Polymers | 1 | 2001 | 1621 | 0.030 |
Why?
|
| Cybernetics | 1 | 1994 | 7 | 0.030 |
Why?
|
| Marfan Syndrome | 1 | 1996 | 237 | 0.030 |
Why?
|
| Sarcoglycans | 1 | 2014 | 57 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2018 | 514 | 0.030 |
Why?
|
| Plasmodium falciparum | 1 | 2024 | 1738 | 0.030 |
Why?
|
| Blood Flow Velocity | 2 | 2001 | 1381 | 0.030 |
Why?
|
| Hypothermia, Induced | 2 | 1996 | 752 | 0.030 |
Why?
|
| Chordae Tendineae | 1 | 1994 | 39 | 0.030 |
Why?
|
| Eflornithine | 1 | 2013 | 31 | 0.030 |
Why?
|
| Mice, Inbred mdx | 1 | 2014 | 90 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 3051 | 0.030 |
Why?
|
| Tensile Strength | 1 | 1995 | 332 | 0.030 |
Why?
|
| Tetracyclines | 1 | 2014 | 64 | 0.030 |
Why?
|
| Ornithine Decarboxylase | 1 | 2013 | 63 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2017 | 912 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2020 | 1707 | 0.030 |
Why?
|
| Aorta | 2 | 1990 | 2028 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 1980 | 1166 | 0.030 |
Why?
|
| Body Burden | 1 | 2014 | 156 | 0.030 |
Why?
|
| Myocardial Infarction | 4 | 1996 | 11501 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1994 | 772 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1994 | 848 | 0.030 |
Why?
|
| Narcotics | 1 | 1996 | 332 | 0.030 |
Why?
|
| Ecology | 1 | 2014 | 105 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 1837 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 2 | 2001 | 2673 | 0.030 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2014 | 116 | 0.030 |
Why?
|
| Phospholipases | 1 | 1973 | 75 | 0.030 |
Why?
|
| Catheterization | 2 | 1996 | 1425 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 1073 | 0.030 |
Why?
|
| Epitopes | 3 | 1977 | 2523 | 0.030 |
Why?
|
| Culture | 1 | 1997 | 622 | 0.030 |
Why?
|
| Reproduction, Asexual | 1 | 2013 | 13 | 0.030 |
Why?
|
| Femoral Artery | 1 | 1997 | 811 | 0.030 |
Why?
|
| Sodium Channel Blockers | 1 | 2014 | 170 | 0.030 |
Why?
|
| Birth Weight | 1 | 2001 | 2122 | 0.030 |
Why?
|
| Workflow | 1 | 2018 | 862 | 0.030 |
Why?
|
| Injections | 1 | 1996 | 840 | 0.030 |
Why?
|
| Polytetrafluoroethylene | 1 | 1994 | 238 | 0.030 |
Why?
|
| Reaction Time | 1 | 1999 | 2086 | 0.030 |
Why?
|
| Digoxin | 1 | 2014 | 246 | 0.030 |
Why?
|
| Sheep, Domestic | 1 | 2012 | 52 | 0.030 |
Why?
|
| Disease Progression | 3 | 2015 | 13631 | 0.030 |
Why?
|
| Follistatin | 1 | 2013 | 138 | 0.030 |
Why?
|
| Point Mutation | 1 | 2018 | 1590 | 0.030 |
Why?
|
| Fatigue | 1 | 2000 | 1549 | 0.030 |
Why?
|
| Cardiac Output | 2 | 1994 | 840 | 0.030 |
Why?
|
| Health Personnel | 1 | 2006 | 3390 | 0.030 |
Why?
|
| Musculoskeletal Physiological Phenomena | 1 | 1993 | 31 | 0.030 |
Why?
|
| Genitalia, Male | 1 | 2013 | 87 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 1996 | 990 | 0.030 |
Why?
|
| Acetanilides | 1 | 2014 | 167 | 0.030 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2001 | 939 | 0.030 |
Why?
|
| Analgesia, Epidural | 1 | 1996 | 337 | 0.030 |
Why?
|
| Yolk Sac | 1 | 2012 | 79 | 0.030 |
Why?
|
| Mice, Inbred Strains | 4 | 1988 | 1770 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 1831 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2015 | 700 | 0.030 |
Why?
|
| Motor Activity | 1 | 2002 | 2704 | 0.030 |
Why?
|
| Deoxyguanine Nucleotides | 1 | 2012 | 22 | 0.030 |
Why?
|
| Antigens | 1 | 2018 | 1438 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2001 | 916 | 0.020 |
Why?
|
| DNA Polymerase I | 1 | 2012 | 44 | 0.020 |
Why?
|
| Fungi | 1 | 1995 | 348 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 2002 | 1287 | 0.020 |
Why?
|
| DNA Polymerase beta | 1 | 2012 | 19 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2017 | 811 | 0.020 |
Why?
|
| Running | 1 | 2017 | 488 | 0.020 |
Why?
|
| Europe | 1 | 1999 | 3423 | 0.020 |
Why?
|
| Erythema Chronicum Migrans | 1 | 1992 | 50 | 0.020 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2012 | 48 | 0.020 |
Why?
|
| Decerebrate State | 1 | 1992 | 42 | 0.020 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2012 | 84 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 1995 | 529 | 0.020 |
Why?
|
| Aorta, Thoracic | 2 | 1996 | 1103 | 0.020 |
Why?
|
| Turtles | 1 | 1992 | 40 | 0.020 |
Why?
|
| Scattering, Radiation | 1 | 1994 | 482 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2019 | 1534 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 1693 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 995 | 0.020 |
Why?
|
| Heart Aneurysm | 1 | 1992 | 115 | 0.020 |
Why?
|
| Community-Acquired Infections | 1 | 1996 | 470 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1996 | 1600 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2017 | 2669 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 1999 | 1820 | 0.020 |
Why?
|
| Hindlimb | 1 | 2014 | 510 | 0.020 |
Why?
|
| Pyrophosphatases | 1 | 2012 | 141 | 0.020 |
Why?
|
| Heart Atria | 3 | 1994 | 1363 | 0.020 |
Why?
|
| DNA Polymerase II | 1 | 2012 | 104 | 0.020 |
Why?
|
| RNA Splicing | 1 | 2016 | 903 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 1385 | 0.020 |
Why?
|
| Lung | 2 | 2001 | 10033 | 0.020 |
Why?
|
| Collateral Circulation | 1 | 1972 | 292 | 0.020 |
Why?
|
| Heart Septum | 1 | 1992 | 303 | 0.020 |
Why?
|
| Endocarditis | 1 | 1995 | 350 | 0.020 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2014 | 479 | 0.020 |
Why?
|
| GATA1 Transcription Factor | 1 | 2012 | 306 | 0.020 |
Why?
|
| DNA Glycosylases | 1 | 2012 | 125 | 0.020 |
Why?
|
| Motion Perception | 1 | 1995 | 377 | 0.020 |
Why?
|
| Healthy Worker Effect | 1 | 2010 | 28 | 0.020 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2012 | 297 | 0.020 |
Why?
|
| Zinc | 1 | 1995 | 675 | 0.020 |
Why?
|
| Genome, Human | 2 | 2016 | 4448 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 1066 | 0.020 |
Why?
|
| Ikaros Transcription Factor | 1 | 2012 | 230 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 36532 | 0.020 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 271 | 0.020 |
Why?
|
| Nitrofurazone | 1 | 2010 | 1 | 0.020 |
Why?
|
| Blotting, Far-Western | 1 | 2010 | 3 | 0.020 |
Why?
|
| Biophysics | 2 | 2004 | 375 | 0.020 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2010 | 17 | 0.020 |
Why?
|
| DNA Primers | 1 | 1995 | 2825 | 0.020 |
Why?
|
| Organ Size | 2 | 2013 | 2261 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1995 | 2229 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 1992 | 445 | 0.020 |
Why?
|
| Body Composition | 1 | 2020 | 2439 | 0.020 |
Why?
|
| Cats | 1 | 1992 | 972 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1983 | 318 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 1992 | 1167 | 0.020 |
Why?
|
| Epilepsy, Generalized | 1 | 2012 | 183 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 1996 | 1048 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 1996 | 2108 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1996 | 1093 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2014 | 1336 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1996 | 712 | 0.020 |
Why?
|
| Breast Feeding | 1 | 2018 | 1363 | 0.020 |
Why?
|
| Valine | 1 | 2011 | 410 | 0.020 |
Why?
|
| Health Resources | 1 | 1996 | 949 | 0.020 |
Why?
|
| Probability | 2 | 2009 | 2475 | 0.020 |
Why?
|
| Heel | 1 | 1990 | 38 | 0.020 |
Why?
|
| Maximum Allowable Concentration | 1 | 2009 | 64 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2015 | 2341 | 0.020 |
Why?
|
| Arthroscopes | 1 | 1989 | 11 | 0.020 |
Why?
|
| Genes, ras | 1 | 2012 | 658 | 0.020 |
Why?
|
| Cytokines | 1 | 2025 | 7421 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 1028 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1977 | 2195 | 0.020 |
Why?
|
| Aortic Diseases | 2 | 1997 | 729 | 0.020 |
Why?
|
| Transfection | 1 | 2017 | 5743 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2001 | 2590 | 0.020 |
Why?
|
| Germany | 1 | 1992 | 882 | 0.020 |
Why?
|
| Hemarthrosis | 1 | 1989 | 39 | 0.020 |
Why?
|
| Neurogenesis | 1 | 2016 | 865 | 0.020 |
Why?
|
| Methionine | 1 | 2011 | 569 | 0.020 |
Why?
|
| No-Observed-Adverse-Effect Level | 1 | 2009 | 25 | 0.020 |
Why?
|
| Thrombectomy | 1 | 1994 | 681 | 0.020 |
Why?
|
| Health Policy | 1 | 2001 | 2698 | 0.020 |
Why?
|
| Methylmethacrylate | 1 | 1989 | 39 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2016 | 1751 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2017 | 2499 | 0.020 |
Why?
|
| Nerve Block | 1 | 1996 | 715 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 1995 | 1175 | 0.020 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2010 | 171 | 0.020 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2012 | 482 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 4108 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 2012 | 431 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2010 | 299 | 0.020 |
Why?
|
| Thrombophlebitis | 1 | 1989 | 286 | 0.020 |
Why?
|
| Animal Experimentation | 1 | 2008 | 46 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1997 | 2020 | 0.020 |
Why?
|
| Social Support | 1 | 1998 | 2192 | 0.020 |
Why?
|
| Epidemics | 1 | 2014 | 514 | 0.020 |
Why?
|
| Mesenteric Arteries | 1 | 1988 | 177 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 1990 | 726 | 0.020 |
Why?
|
| Prevalence | 1 | 2005 | 15839 | 0.020 |
Why?
|
| Endoribonucleases | 1 | 2009 | 229 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2014 | 14447 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2012 | 1061 | 0.020 |
Why?
|
| Program Development | 1 | 1994 | 1295 | 0.020 |
Why?
|
| Prednisone | 1 | 2012 | 1565 | 0.020 |
Why?
|
| Danazol | 1 | 2007 | 44 | 0.020 |
Why?
|
| Artifacts | 1 | 1996 | 1893 | 0.020 |
Why?
|
| Hypnotics and Sedatives | 1 | 1995 | 1191 | 0.020 |
Why?
|
| Acne Vulgaris | 1 | 1993 | 352 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 1999 | 3211 | 0.020 |
Why?
|
| Myxoma | 1 | 1988 | 115 | 0.020 |
Why?
|
| Endarterectomy, Carotid | 1 | 1992 | 557 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2012 | 1024 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 2 | 1989 | 744 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2012 | 864 | 0.020 |
Why?
|
| Bronchi | 1 | 1991 | 843 | 0.020 |
Why?
|
| Back Injuries | 1 | 2007 | 41 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 4642 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2014 | 1611 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 1992 | 1731 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2007 | 150 | 0.020 |
Why?
|
| Wound Infection | 1 | 1989 | 244 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2011 | 1560 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2007 | 107 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 1998 | 2709 | 0.020 |
Why?
|
| Ovulation | 1 | 2007 | 178 | 0.020 |
Why?
|
| Echocardiography | 4 | 1992 | 5045 | 0.020 |
Why?
|
| Pleural Neoplasms | 1 | 1991 | 581 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 1972 | 1602 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2012 | 2601 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1899 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2018 | 4752 | 0.020 |
Why?
|
| Mutagenicity Tests | 1 | 2005 | 46 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2015 | 2589 | 0.020 |
Why?
|
| Carcinogenicity Tests | 1 | 2005 | 39 | 0.020 |
Why?
|
| Quality of Life | 2 | 2020 | 13461 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1981 | 1347 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3655 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 1638 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2015 | 3222 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 2720 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2014 | 2143 | 0.020 |
Why?
|
| Heart Diseases | 3 | 1994 | 2821 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2020 | 6425 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 1989 | 500 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2013 | 2729 | 0.020 |
Why?
|
| Pulmonary Veins | 1 | 1991 | 757 | 0.020 |
Why?
|
| Mesothelioma | 1 | 1991 | 771 | 0.020 |
Why?
|
| Heart Rate | 4 | 2001 | 4203 | 0.020 |
Why?
|
| Lead | 1 | 2011 | 879 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 1624 | 0.020 |
Why?
|
| Acetates | 1 | 1986 | 313 | 0.010 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 827 | 0.010 |
Why?
|
| Computers, Molecular | 1 | 2004 | 12 | 0.010 |
Why?
|
| Fertilizers | 1 | 2004 | 24 | 0.010 |
Why?
|
| Sirolimus | 1 | 2011 | 1545 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2013 | 4137 | 0.010 |
Why?
|
| Comorbidity | 1 | 2019 | 10563 | 0.010 |
Why?
|
| Aneurysm | 1 | 1988 | 337 | 0.010 |
Why?
|
| Fixatives | 1 | 2004 | 90 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1990 | 1339 | 0.010 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1988 | 540 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 4348 | 0.010 |
Why?
|
| Decision Making | 1 | 1998 | 3965 | 0.010 |
Why?
|
| Heart Neoplasms | 1 | 1988 | 375 | 0.010 |
Why?
|
| Macrophages | 2 | 2014 | 5772 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 1991 | 1128 | 0.010 |
Why?
|
| Intestinal Diseases | 1 | 1989 | 506 | 0.010 |
Why?
|
| Oscillometry | 1 | 2004 | 151 | 0.010 |
Why?
|
| Protective Devices | 1 | 2004 | 72 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1992 | 1383 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 2880 | 0.010 |
Why?
|
| Liver | 1 | 2019 | 7562 | 0.010 |
Why?
|
| Coronary Angiography | 2 | 1994 | 4494 | 0.010 |
Why?
|
| Connecticut | 1 | 1984 | 365 | 0.010 |
Why?
|
| Adenocarcinoma | 2 | 1978 | 6364 | 0.010 |
Why?
|
| Strontium Radioisotopes | 1 | 1983 | 18 | 0.010 |
Why?
|
| Piperazines | 1 | 2014 | 2549 | 0.010 |
Why?
|
| Electronics | 1 | 2004 | 314 | 0.010 |
Why?
|
| Disinfectants | 1 | 2004 | 130 | 0.010 |
Why?
|
| Cortisone | 1 | 1983 | 90 | 0.010 |
Why?
|
| Work Schedule Tolerance | 1 | 2006 | 554 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1991 | 1935 | 0.010 |
Why?
|
| Morbidity | 2 | 1999 | 1749 | 0.010 |
Why?
|
| Biological Transport | 1 | 2007 | 2081 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 1983 | 438 | 0.010 |
Why?
|
| Ireland | 1 | 2002 | 170 | 0.010 |
Why?
|
| Eating | 1 | 1988 | 1539 | 0.010 |
Why?
|
| Dobutamine | 1 | 1982 | 114 | 0.010 |
Why?
|
| Carcinoma, Ehrlich Tumor | 1 | 1981 | 23 | 0.010 |
Why?
|
| Cost Savings | 1 | 2007 | 904 | 0.010 |
Why?
|
| Pancreas | 1 | 1988 | 1700 | 0.010 |
Why?
|
| Textile Industry | 1 | 2001 | 74 | 0.010 |
Why?
|
| Atrial Fibrillation | 2 | 1998 | 5189 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 1972 | 3097 | 0.010 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1981 | 175 | 0.010 |
Why?
|
| tau Proteins | 1 | 2011 | 2112 | 0.010 |
Why?
|
| Prognosis | 3 | 2012 | 29921 | 0.010 |
Why?
|
| Aortic Valve Insufficiency | 2 | 1982 | 575 | 0.010 |
Why?
|
| Catecholamines | 1 | 1982 | 383 | 0.010 |
Why?
|
| Vietnam | 1 | 2001 | 411 | 0.010 |
Why?
|
| Warfarin | 1 | 1989 | 1494 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2002 | 766 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1989 | 1203 | 0.010 |
Why?
|
| Workload | 1 | 2006 | 851 | 0.010 |
Why?
|
| DNA, Ribosomal | 1 | 2002 | 300 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2018 | 4873 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2005 | 1370 | 0.010 |
Why?
|
| Power Plants | 1 | 1981 | 125 | 0.010 |
Why?
|
| Documentation | 1 | 2007 | 916 | 0.010 |
Why?
|
| Thrombosis | 1 | 1994 | 2949 | 0.010 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2012 | 2531 | 0.010 |
Why?
|
| Middle Cerebral Artery | 1 | 2001 | 268 | 0.010 |
Why?
|
| Survivors | 1 | 2010 | 2372 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1992 | 2159 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 2001 | 1300 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2001 | 276 | 0.010 |
Why?
|
| Swine | 1 | 1989 | 5988 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1970 | 3454 | 0.010 |
Why?
|
| Streptococcal Infections | 2 | 1994 | 617 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 2 | 1998 | 1470 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1994 | 4058 | 0.010 |
Why?
|
| Immunization | 2 | 1973 | 1219 | 0.010 |
Why?
|
| Socioeconomic Factors | 2 | 2011 | 7836 | 0.010 |
Why?
|
| Antibodies | 2 | 1981 | 2417 | 0.010 |
Why?
|
| HIV Infections | 1 | 2005 | 17533 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2006 | 1406 | 0.010 |
Why?
|
| Brain | 3 | 2014 | 27178 | 0.010 |
Why?
|
| Rauscher Virus | 1 | 1978 | 13 | 0.010 |
Why?
|
| Partial Pressure | 1 | 1998 | 245 | 0.010 |
Why?
|
| Neoplasms, Experimental | 2 | 1973 | 1229 | 0.010 |
Why?
|
| Moloney murine leukemia virus | 1 | 1978 | 110 | 0.010 |
Why?
|
| AKR murine leukemia virus | 1 | 1977 | 3 | 0.010 |
Why?
|
| Respiratory Protective Devices | 1 | 1998 | 47 | 0.010 |
Why?
|
| Multivariate Analysis | 3 | 1996 | 12057 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1977 | 173 | 0.010 |
Why?
|
| Particle Size | 1 | 2001 | 1631 | 0.010 |
Why?
|
| Antibodies, Heterophile | 1 | 1977 | 128 | 0.010 |
Why?
|
| Illinois | 1 | 1997 | 120 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1983 | 2228 | 0.010 |
Why?
|
| Rabbits | 2 | 1973 | 4734 | 0.010 |
Why?
|
| Ventricular Function | 1 | 1998 | 403 | 0.010 |
Why?
|
| Lymphocytes | 2 | 1978 | 2599 | 0.010 |
Why?
|
| Combined Modality Therapy | 3 | 1994 | 8529 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 1987 | 1604 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 1999 | 993 | 0.010 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1998 | 389 | 0.010 |
Why?
|
| Postoperative Care | 2 | 1996 | 1470 | 0.010 |
Why?
|
| Plasma Substitutes | 1 | 1976 | 57 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1977 | 1140 | 0.010 |
Why?
|
| Clavicle | 1 | 1997 | 224 | 0.010 |
Why?
|
| Wrist | 1 | 1996 | 231 | 0.010 |
Why?
|
| Postoperative Hemorrhage | 1 | 1998 | 413 | 0.010 |
Why?
|
| Capsid | 1 | 1977 | 435 | 0.010 |
Why?
|
| Dopamine | 1 | 1982 | 1582 | 0.010 |
Why?
|
| Angina Pectoris | 1 | 1978 | 956 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1996 | 682 | 0.010 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1997 | 516 | 0.010 |
Why?
|
| Range of Motion, Articular | 1 | 2001 | 1594 | 0.010 |
Why?
|
| Embolism | 1 | 1997 | 400 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1989 | 12976 | 0.010 |
Why?
|
| Equipment Failure | 2 | 1989 | 578 | 0.010 |
Why?
|
| Catheterization, Peripheral | 1 | 1997 | 349 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1998 | 1816 | 0.010 |
Why?
|
| Cardiovascular Diseases | 2 | 2009 | 15651 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 21056 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 1998 | 1191 | 0.010 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 1973 | 138 | 0.010 |
Why?
|
| Fetal Proteins | 1 | 1973 | 99 | 0.010 |
Why?
|
| Curriculum | 1 | 2006 | 3782 | 0.010 |
Why?
|
| Neuraminidase | 1 | 1973 | 190 | 0.010 |
Why?
|
| Immune Sera | 1 | 1973 | 601 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1973 | 274 | 0.010 |
Why?
|
| Sex Distribution | 1 | 1998 | 2263 | 0.010 |
Why?
|
| Trypsin | 1 | 1973 | 487 | 0.010 |
Why?
|
| Life Tables | 1 | 1992 | 363 | 0.010 |
Why?
|
| Thoracotomy | 1 | 1994 | 369 | 0.010 |
Why?
|
| Xenon | 1 | 1972 | 120 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1980 | 1171 | 0.010 |
Why?
|
| Age Distribution | 1 | 1998 | 2858 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2001 | 8532 | 0.010 |
Why?
|
| Stroke Volume | 2 | 1998 | 5596 | 0.010 |
Why?
|
| Hospital Mortality | 2 | 1998 | 5343 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 18071 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1996 | 1689 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1988 | 8927 | 0.010 |
Why?
|
| Dinitrophenols | 1 | 1970 | 56 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1996 | 1515 | 0.010 |
Why?
|
| Hand | 1 | 1996 | 909 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1999 | 1620 | 0.010 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 1970 | 87 | 0.010 |
Why?
|
| gamma-Globulins | 1 | 1970 | 119 | 0.010 |
Why?
|
| Demography | 2 | 1989 | 1641 | 0.010 |
Why?
|
| Wales | 1 | 1971 | 87 | 0.010 |
Why?
|
| Isoantigens | 1 | 1973 | 562 | 0.010 |
Why?
|
| Radioisotopes | 1 | 1972 | 495 | 0.010 |
Why?
|
| Haptens | 1 | 1970 | 163 | 0.010 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 1997 | 700 | 0.010 |
Why?
|
| Tissue Extracts | 1 | 1970 | 139 | 0.010 |
Why?
|
| Population Density | 1 | 1971 | 193 | 0.010 |
Why?
|
| Whooping Cough | 1 | 1971 | 87 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1970 | 515 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1970 | 318 | 0.010 |
Why?
|
| Rosette Formation | 2 | 1981 | 152 | 0.010 |
Why?
|
| Carbon Isotopes | 1 | 1970 | 451 | 0.010 |
Why?
|
| Emergencies | 1 | 1996 | 1223 | 0.010 |
Why?
|
| Accidents | 1 | 1971 | 164 | 0.010 |
Why?
|
| Pleura | 1 | 1991 | 240 | 0.010 |
Why?
|
| Crowding | 1 | 1971 | 142 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 1999 | 2003 | 0.010 |
Why?
|
| Diaphragm | 1 | 1991 | 356 | 0.010 |
Why?
|
| HLA-A Antigens | 1 | 1990 | 223 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1992 | 778 | 0.010 |
Why?
|
| Computers | 1 | 1972 | 588 | 0.000 |
Why?
|
| Radiography | 2 | 1992 | 6919 | 0.000 |
Why?
|
| Ear Diseases | 1 | 1971 | 179 | 0.000 |
Why?
|
| Antibody Specificity | 1 | 1970 | 1061 | 0.000 |
Why?
|
| Lectins | 1 | 1970 | 487 | 0.000 |
Why?
|
| Culture Media | 1 | 1970 | 890 | 0.000 |
Why?
|
| HLA-B Antigens | 1 | 1990 | 329 | 0.000 |
Why?
|
| Estrus | 1 | 1988 | 70 | 0.000 |
Why?
|
| Paralysis | 1 | 1990 | 248 | 0.000 |
Why?
|
| Methylprednisolone | 1 | 1990 | 386 | 0.000 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 1998 | 1566 | 0.000 |
Why?
|
| HLA-DR Antigens | 1 | 1990 | 608 | 0.000 |
Why?
|
| Antilymphocyte Serum | 1 | 1990 | 493 | 0.000 |
Why?
|
| Transplantation, Homologous | 2 | 1992 | 4860 | 0.000 |
Why?
|
| Education | 1 | 1971 | 533 | 0.000 |
Why?
|
| Veterans | 1 | 2001 | 2664 | 0.000 |
Why?
|
| Perfusion | 1 | 1972 | 1407 | 0.000 |
Why?
|
| Immunoglobulins | 1 | 1970 | 852 | 0.000 |
Why?
|
| Intraoperative Period | 1 | 1988 | 508 | 0.000 |
Why?
|
| Hemolysis | 1 | 1989 | 406 | 0.000 |
Why?
|
| Angiography | 1 | 1972 | 1581 | 0.000 |
Why?
|
| Arteries | 1 | 1992 | 1118 | 0.000 |
Why?
|
| Echocardiography, Doppler | 1 | 1991 | 899 | 0.000 |
Why?
|
| Pericardium | 1 | 1991 | 679 | 0.000 |
Why?
|
| Kidney Neoplasms | 2 | 1973 | 4274 | 0.000 |
Why?
|
| Laparotomy | 1 | 1989 | 460 | 0.000 |
Why?
|
| Immunologic Memory | 1 | 1973 | 1375 | 0.000 |
Why?
|
| Congenital Abnormalities | 1 | 1971 | 704 | 0.000 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1996 | 2136 | 0.000 |
Why?
|
| Antigens, Neoplasm | 1 | 1973 | 2002 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 2001 | 15398 | 0.000 |
Why?
|
| Saphenous Vein | 1 | 1988 | 511 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1972 | 1792 | 0.000 |
Why?
|
| Spermatozoa | 1 | 1988 | 629 | 0.000 |
Why?
|
| Heart Failure | 1 | 1987 | 11840 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1996 | 6404 | 0.000 |
Why?
|
| Anticoagulants | 1 | 1998 | 4862 | 0.000 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1992 | 2247 | 0.000 |
Why?
|
| Length of Stay | 1 | 1996 | 6485 | 0.000 |
Why?
|
| Stimulation, Chemical | 1 | 1982 | 303 | 0.000 |
Why?
|
| Social Class | 1 | 1971 | 2007 | 0.000 |
Why?
|
| Graft Survival | 1 | 1992 | 3890 | 0.000 |
Why?
|
| Binding Sites, Antibody | 1 | 1981 | 340 | 0.000 |
Why?
|
| Ascitic Fluid | 1 | 1981 | 190 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 1972 | 3312 | 0.000 |
Why?
|
| Myocardium | 1 | 1972 | 4760 | 0.000 |
Why?
|
| Influenza, Human | 1 | 1971 | 1539 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1992 | 5993 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 1997 | 5197 | 0.000 |
Why?
|
| Pneumonia | 1 | 1971 | 2157 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1988 | 2267 | 0.000 |
Why?
|
| Intensive Care Units | 1 | 1972 | 3800 | 0.000 |
Why?
|
| Tuberculosis | 1 | 1971 | 2012 | 0.000 |
Why?
|
| Hemorrhage | 1 | 1989 | 3461 | 0.000 |
Why?
|
| Obesity | 1 | 1999 | 13075 | 0.000 |
Why?
|
| Electroencephalography | 1 | 1992 | 6273 | 0.000 |
Why?
|
| Life Expectancy | 1 | 1981 | 1247 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1990 | 9249 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1991 | 11868 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1978 | 4528 | 0.000 |
Why?
|